CUMULATIVE
SUPPLEMENT 6
JUNE 2002



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2002

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

Cumulative Supplement 6

June 2002

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

22ND EDITION

CUMULATIVE SUPPLEMENT 6
June 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DANBURY PHARMACEUTICALS INC (DANBURY PHARMA)	WATSON LABORATORIES INC (WATSON LABS)
DURAMED PHARMACEUTICALS INC (DURAMED)	DURAMED PHARMACEUTICALS INC SUB OF BARR LABORATORIES INC (DURAMED PHARM BARR)
DERMIK LABORATORIES INC (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
JANSSEN RESEARCH FDN (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC (JOHNSON AND JOHNSON)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
MCNEIL CONSUMER HEALTHCARE DIVISION (MCNEIL CONS)	MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIVISION MCNEIL PPC (MCNEIL CONS SPECLT)
MOVA PHARMACEUTICALS CORPORATION (MOVA)	CLONMEL HEALTHCARE LTD (CLONMEL HLTH)
PARKE DAVIS PHARMACEUTICALS LTD (PARKE DAVIS PHARMS)	PFIZER PHARMACEUTICALS LTD (PFIZER PHARM LTD)
THAMES PHARMACAL COMPANY INC (THAMES)	TARO PHARMACEUTICALS NORTH AMERICA INC (TARO PHARMS US)
WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)
WHITEHALL ROBINS HEALTHCARE (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waiver its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waivers its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity

1.4 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/22bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.
The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2001	MAR 2002	JUN 2002	SEP 2002
DRUG PRODUCTS LISTED	10166	10357	10193	
SINGLE SOURCE	2665 26.2%)	2645 (25.5%)	2400 (23.5%)	
MULTISOURCE	7391 72.7%)	7602 (73.4%)	7687 (75.4%)	
THERAPEUTICALLY EQUIVALENT	7105 69.9%)	7309 (70.6%)	7402 (72.6%)	
NOT THERAPEUTICALLY EQUIVALENT	286 (2.8%)	293 (2.8%)	285 (2.8%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	106 (1.0%)	
NEW MOLECULAR ENTITIES APPROVED	10	1	5	
NUMBER OF APPLICANTS	574	574	574	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE						
	AB	VINTAGE PHARMS	325MG;50MG;40MG;30MG	N75929 001	APR 22, 2002	APR	NEWA
		ACETAMINOPHEN; CODEINE PHOSPHATE						
		. CAPSULE; ORAL						
		PHENAPHEN W/ CODEINE NO. 2						
		@ ROBINS AH	325MG;15MG	N84444 001		MAY	DISC
		SOLUTION; ORAL						
		ACETAMINOPHEN AND CODEINE PHOSPHATE						
	AA +	ALPHARMA	120MG/5ML;12MG/5ML	N85861 001		MAY	CRLD
		TYLENOL W/ CODEINE						
		@ JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001		MAY	DISC
		TABLET; ORAL						
		ACETAMINOPHEN AND CODEINE PHOSPHATE						
		@ PUREPAC PHARM	300MG;60MG	N86683 001		MAY	DISC
		ACETAMINOPHEN; HYDROCODONE BITARTRATE						
		SOLUTION; ORAL						
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	AA	KV PHARM	500MG/15ML;7.5MG/15ML	N40366 001	JAN 23, 2002	JAN	NEWA
		TABLET; ORAL						
>D>	AA	PEACHTREE	500MG;10MG	N40210 001	AUG 13, 1997	JUN	CAHN
>A>	AA	UCB	500MG;10MG	N40210 001	AUG 13, 1997	JUN	CAHN
		NORCO						
	AA +	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	MAY	CTNA
		ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE						
		TABLET; ORAL						
		DARVOCET						
>A>		@ AAIPHARMA LLC	325MG;32.5MG	N16844 001		JUN	CAHN
>D>		@ LILLY	325MG;32.5MG	N16844 001		JUN	CAHN
		ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE						
		TABLET; ORAL						
		DARVOCET-N 100						
>A>	AB +	AAIPHARMA LLC	650MG;100MG	N17122 002		JUN	CAHN
>D>	AB +	LILLY	650MG;100MG	N17122 002		JUN	CAHN
		DARVOCET-N 50						
>A>	AB	AAIPHARMA LLC	325MG;50MG	N17122 001		JUN	CAHN
>D>	AB	LILLY	325MG;50MG	N17122 001		JUN	CAHN
		ALBUMIN CHROMATED CR-51 SERUM						
>D>		INJECTABLE; INJECTION						
>D>		CHROMALBIN						
>D>		ISO TEX	100uCi/VIAL	N17835 001		JUN	DISC
>A>		@	100uCi/VIAL	N17835 001		JUN	DISC

		ALBUMIN IODINATED I-125 SERUM						
>D>		INJECTABLE; INJECTION						
>D>		RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125						
>D>		MALLINCKRODT	6.67uCi/ML	N17844 003		JUN	DISC	
>A>		@	6.67uCi/ML	N17844 003		JUN	DISC	
>D>			100uCi/ML	N17844 002		JUN	DISC	
>A>		@	100uCi/ML	N17844 002		JUN	DISC	
		ALBUTEROL						
		AEROSOL, METERED; INHALATION						
		PROVENTIL						
>D>	BN	SCHERING	0.09MG/INH	N17559 001		JUN	CRLD	
>A>	BN +		0.09MG/INH	N17559 001		JUN	CRLD	
		ALBUTEROL SULFATE						
		AEROSOL, METERED; INHALATION						
		PROVENTIL-HFA						
	BX +	3M	EQ 0.09MG BASE/INH	N20503 001	AUG 15, 1996	MAR	CTEC	
		VENTOLIN HFA						
	BX +	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	MAR	CTEC	
		ALGLUCERASE						
		INJECTABLE; INJECTION						
		CEREDASE						
>D>		GENZYME	10 UNITS/ML	N20057 004	MAY 08, 1992	JUN	DISC	
>A>		@	10 UNITS/ML	N20057 004	MAY 08, 1992	JUN	DISC	
		ALLOPURINOL SODIUM						
		INJECTABLE; INJECTION						
		ALOPRIM						
>D>		+ CATALYTICA PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996	JUN	CAHN	
>A>		+ DSM PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996	JUN	CAHN	
		ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE						
		INJECTABLE; INJECTION						
		MULTI-12						
		+ SABEX 2002	2 IU/ML;20MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/ML;0.8MG/ML;0.72MG/ML;0.6MG/ML;600 IU/ML	N21163 001	MAY 18, 2000	APR	CAHN	
		ALPROSTADIL						
		INJECTABLE; INJECTION						
		CAVERJECT						
>A>		PHARMACIA AND UPJOHN	0.01MG/VIAL	N21212 001	JUN 11, 2002	JUN	NEWA	
>A>			0.02MG/VIAL	N21212 002	JUN 11, 2002	JUN	NEWA	

AMIFOSTINE
INJECTABLE; INJECTION
ETHYOL

>D>		MEDIMMUNE ONCOLOGY	375MG/VIAL	N20221 002	SEP 10, 1999	JUN	DISC
>A>		@	375MG/VIAL	N20221 002	SEP 10, 1999	JUN	DISC

AMINO ACIDS
INJECTABLE; INJECTION

>D>		AMINOSYN 7%					
>D>		ABBOTT	7% (7GM/100ML)	N17673 002		JUN	DISC
>A>		@	7% (7GM/100ML)	N17673 002		JUN	DISC
>D>		AMINOSYN 8.5%					
>D>		ABBOTT	8.5% (8.5GM/100ML)	N17673 004		JUN	DISC
>A>		@	8.5% (8.5GM/100ML)	N17673 004		JUN	DISC
>D>		AMINOSYN II 3.5%					
>D>		ABBOTT	3.5% (3.5GM/100ML)	N19438 001	APR 03, 1986	JUN	DISC
>A>		@	3.5% (3.5GM/100ML)	N19438 001	APR 03, 1986	JUN	DISC
>D>		BRANCHAMIN 4%					
>D>		BAXTER HLTHCARE	4% (4GM/100ML)	N18678 001	SEP 28, 1984	JUN	DISC
>A>		@	4% (4GM/100ML)	N18678 001	SEP 28, 1984	JUN	DISC

AMMONIUM LACTATE
CREAM; TOPICAL
AMMONIUM LACTATE

	AB	CLAY PARK	EQ 12% BASE	N75774 001	MAY 01, 2002	MAY	NEWA

LAC-HYDRIN

	AB +	WESTWOOD SQUIBB	EQ 12% BASE	N20508 001	AUG 29, 1996	MAY	CFTG

LOTION; TOPICAL
AMMONIUM LACTATE

>A>							
>A>	AB	PADDOCK	EQ 12% BASE	N75575 001	JUN 11, 2002	JUN	NEWA

LAC-HYDRIN

>D>	+	WESTWOOD SQUIBB	EQ 12% BASE	N19155 001	APR 24, 1985	JUN	CFTG
>A>	AB +		EQ 12% BASE	N19155 001	APR 24, 1985	JUN	CFTG

AMOXICILLIN; CLAVULANATE POTASSIUM
FOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

>A>							
>A>	AB	GENEVA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	N65066 001	JUN 05, 2002	JUN	NEWA
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	N65066 002	JUN 05, 2002	JUN	NEWA

AUGMENTIN '200'

>D>		GLAXOSMITHKLINE	200MG/5ML;EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996	JUN	CFTG
>A>	AB		200MG/5ML;EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996	JUN	CFTG

AUGMENTIN '400'

>D>		GLAXOSMITHKLINE	400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	JUN	CFTG
>A>	AB		400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	JUN	CFTG
			400MG/5ML;EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996	FEB	CRLD

TABLET; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

	AB	GENEVA PHARMS	500MG;EQ 125MG BASE	N65064 001	MAR 15, 2002	MAR	NEWA
	AB		875MG;EQ 125MG BASE	N65063 001	MAR 14, 2002	MAR	NEWA

AUGMENTIN '500'

	AB	GLAXOSMITHKLINE	500MG;EQ 125MG BASE	N50564 002	AUG 06, 1984	MAR	CFTG

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AUGMENTIN '875'

AB	+	GLAXOSMITHKLINE	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996	MAR	CFTG

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		GENEVA PHARMS	200MG;EQ 28.5MG BASE	N65065 001	APR 18, 2002	APR	NEWA
AB			400MG;EQ 57MG BASE	N65065 002	APR 18, 2002	APR	NEWA

AUGMENTIN '200'

AB		GLAXOSMITHKLINE	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996	APR	CFTG

AUGMENTIN '400'

AB	+	GLAXOSMITHKLINE	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996	APR	CFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 15

>A>		SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N21303 006	MAY 22, 2002	JUN	NEWA

ADDERALL XR 25

>A>		SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JUN	NEWA

ADDERALL XR 5

>A>		SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JUN	NEWA

TABLET; ORAL

ADDERALL 10

AB		SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	FEB 13, 1996	FEB	CFTG

ADDERALL 20

AB		SHIRE LABS	5MG;5MG;5MG;5MG	N11522 008	FEB 13, 1996	FEB	CFTG

ADDERALL 30

AB	+	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010	MAY 12, 1997	FEB	CFTG

ADDERALL 5

AB		SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N11522 009	MAY 12, 1997	FEB	CFTG

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		BARR	1.25MG;1.25MG;1.25MG;1.25MG	N40422 001	FEB 11, 2002	FEB	NEWA
AB			2.5MG;2.5MG;2.5MG;2.5MG	N40422 002	FEB 11, 2002	FEB	NEWA
AB			5MG;5MG;5MG;5MG	N40422 003	FEB 11, 2002	FEB	NEWA
AB			7.5MG;7.5MG;7.5MG;7.5MG	N40422 004	FEB 11, 2002	FEB	NEWA
>A> AB		COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	N40444 001	JUN 19, 2002	JUN	NEWA
>A> AB			2.5MG;2.5MG;2.5MG;2.5MG	N40444 002	JUN 19, 2002	JUN	NEWA
>A> AB			5MG;5MG;5MG;5MG	N40444 003	JUN 19, 2002	JUN	NEWA
>A> AB			7.5MG;7.5MG;7.5MG;7.5MG	N40444 004	JUN 19, 2002	JUN	NEWA
>A> AB		EON	2.5MG;2.5MG;2.5MG;2.5MG	N40439 001	JUN 14, 2002	JUN	NEWA
>A> AB			5MG;5MG;5MG;5MG	N40439 002	JUN 14, 2002	JUN	NEWA
>A> AB			7.5MG;7.5MG;7.5MG;7.5MG	N40439 003	JUN 14, 2002	JUN	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

	+	ELAN PHARMS	5MG/ML	N50724 001	NOV 20, 1995	JAN	CAHN

>D>		SUSPENSION; ORAL						
>D>		FUNGIZONE						
>D>		+ BRISTOL MYERS SQUIBB	100MG/ML	N50341 003		JUN	DISC
>A>		@	100MG/ML	N50341 003		JUN	DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM
INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP		ESI LEDERLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	MAR 19, 2002	MAR	NEWA
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	MAR 19, 2002	MAR	NEWA
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	MAR 19, 2002	MAR	NEWA
		UNASYN					
AP	+	PFIZER	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N50608 002	DEC 31, 1986	MAR	CFTG
AP	+		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N50608 001	DEC 31, 1986	MAR	CFTG
AP	+		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N50608 005	DEC 10, 1993	MAR	CFTG

AMPRENAVIR
CAPSULE; ORAL
AGENERASE

	@	GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999	MAY	DISC
	@		150MG	N21007 002	APR 15, 1999	MAY	DISC

SOLUTION; ORAL

	@	GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999	MAY	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
INJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC

+		SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	APR	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
DARVON COMPOUND

>A>		+	AAIPHARMA LLC	389MG;32.4MG;32MG	N10996 006	MAR 08, 1983	JUN	CAHN
>D>		+	LILLY	389MG;32.4MG;32MG	N10996 006	MAR 08, 1983	JUN	CAHN
			DARVON COMPOUND-65					
>A>	AA	+	AAIPHARMA LLC	389MG;32.4MG;65MG	N10996 007	MAR 08, 1983	JUN	CAHN
>D>	AA	+	LILLY	389MG;32.4MG;65MG	N10996 007	MAR 08, 1983	JUN	CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE
>D> TABLET; ORAL
>D> TALWIN COMPOUND

>D>	+	SANOFI SYNTHELABO	325MG;EQ 12.5MG BASE	N16891 001		JUN	DISC
>A>	@		325MG;EQ 12.5MG BASE	N16891 001		JUN	DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE
>D> CAPSULE; ORAL
>D> DARVON W/ ASA

>A>	+	AAIPHARMA LLC	325MG;65MG	N10996 005		JUN	CAHN
>D>	+	LILLY	325MG;65MG	N10996 005		JUN	CAHN

	ASPIRIN; PROPOXYPHENE NAPSYLATE						
	CAPSULE; ORAL						
	DARVON-N W/ ASA						
>A>	@ AAIPHARMA LLC	325MG;100MG	N16829 001			JUN	CAHN
>D>	@ LILLY	325MG;100MG	N16829 001			JUN	CAHN
	TABLET; ORAL						
>A>	@ AAIPHARMA LLC	325MG;100MG	N16863 001			JUN	CAHN
>D>	@ LILLY	325MG;100MG	N16863 001			JUN	CAHN
	ATROPINE; PRALIDOXIME CHLORIDE						
	INJECTABLE; INTRAMUSCULAR						
	ATNAA						
	+ @ US ARMY	2.1MG/0.7ML;600MG/2ML	N21175 001	JAN 17, 2002		JAN	NEWA
	@	2.1MG/0.7ML;600MG/2ML	N21175 001	JAN 17, 2002		FEB	NEWA
	AZELASTINE HYDROCHLORIDE						
	SOLUTION/DROPS; OPHTHALMIC						
	OPTIVAR						
	+ MURO	0.05%	N21127 001	MAY 22, 2000		MAY	CAHN
	AZITHROMYCIN DIHYDRATE						
	TABLET; ORAL						
	ZITHROMAX						
	+ PFIZER	EQ 500MG BASE	N50784 001	MAY 24, 2002		MAY	NEWA
	AZTREONAM						
	INJECTABLE; INJECTION						
>D>	AZACTAM						
>D>	+ BRISTOL MYERS SQUIBB	500MG/VIAL	N50580 001	DEC 31, 1986		JUN	DISC
>A>	@	500MG/VIAL	N50580 001	DEC 31, 1986		JUN	DISC
>D>	+	1GM/VIAL	N50580 002	DEC 31, 1986		JUN	DISC
>A>	@	1GM/VIAL	N50580 002	DEC 31, 1986		JUN	DISC
>D>	+	2GM/VIAL	N50580 003	DEC 31, 1986		JUN	DISC
>A>	@	2GM/VIAL	N50580 003	DEC 31, 1986		JUN	DISC
	BACITRACIN ZINC; POLYMYXIN B SULFATE						
	OINTMENT; OPHTHALMIC						
	BACITRACIN ZINC AND POLYMYXIN B SULFATE						
AT	ALTANA	500 UNITS/GM;10,000 UNITS/GM	N65022 001	FEB 27, 2002		FEB	NEWA
	BENDROFLUMETHIAZIDE						
	TABLET; ORAL						
>D>	NATURETIN-10						
>D>	+ APOTHECON	10MG	N12164 003			JUN	DISC
>A>	@	10MG	N12164 003			JUN	DISC
	NATURETIN-5						
>D>	APOTHECON	5MG	N12164 002			JUN	CRLD
>A>	+	5MG	N12164 002			JUN	CRLD

BENZONATATE
CAPSULE; ORAL
TESSALON
\+ FOREST LABS 200MG N11210 003 JUN 25, 1999 MAR NEWA

BENZTROPINE MESYLATE
TABLET; ORAL
BENZTROPINE MESYLATE
AA COREPHARMA 0.5MG N72264 001 FEB 27, 1989 MAY CAHN
AA 1MG N72265 001 FEB 27, 1989 MAY CAHN
AA 2MG N72266 001 FEB 27, 1989 MAY CAHN

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE
>D> TABLET; ORAL
>D> KERLEDEX
>D> LOREX 5MG;12.5MG N19807 001 OCT 30, 1992 JUN DISC
>A> @ 5MG;12.5MG N19807 001 OCT 30, 1992 JUN DISC
>D> + 10MG;12.5MG N19807 002 OCT 30, 1992 JUN DISC
>A> @ 10MG;12.5MG N19807 002 OCT 30, 1992 JUN DISC

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE
>D> SUSPENSION/DROPS; OPHTHALMIC
>D> BETOPTIC PILO
>D> + ALCON EQ 0.25% BASE;1.75% N20619 001 APR 17, 1997 JUN DISC
>A> @ EQ 0.25% BASE;1.75% N20619 001 APR 17, 1997 JUN DISC

BIPERIDEN LACTATE
>D> INJECTABLE; INJECTION
>D> AKINETON
>D> + ABBOTT 5MG/ML N12418 002 JUN DISC
>A> @ 5MG/ML N12418 002 JUN DISC

BITOLTEROL MESYLATE
>D> AEROSOL, METERED; INHALATION
>D> TORNALATE
>D> + SANOFI SYNTHELABO 0.37MG/INH N18770 001 DEC 28, 1984 JUN DISC
>A> @ 0.37MG/INH N18770 001 DEC 28, 1984 JUN DISC
SOLUTION; INHALATION
>D> SANOFI SYNTHELABO 0.2% N19548 001 FEB 19, 1992 JUN DISC
>A> @ 0.2% N19548 001 FEB 19, 1992 JUN DISC

BROMOCRIPTINE MESYLATE
TABLET; ORAL
BROMOCRIPTINE MESYLATE
AB LEK SVCS EQ 2.5MG BASE N74631 001 JAN 13, 1998 JAN CMFD
PARLODEL
AB + NOVARTIS EQ 2.5MG BASE N17962 001 JAN CFTG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
SYRUP; ORAL
BROMANYL
@ ALPHARMA 12.5MG/5ML;10MG/5ML N88343 001 AUG 15, 1984 MAY DISC

BUPIVACAINE HYDROCHLORIDE

		INJECTABLE; INJECTION						
>D>		BUPIVACAINE HCL KIT						
>D>		ABBOTT	0.075%	N19978	001	SEP 03, 1992	JUN	DISC
>A>		ⓐ	0.075%	N19978	001	SEP 03, 1992	JUN	DISC
>D>			0.114%	N19978	002	SEP 03, 1992	JUN	DISC
>A>		ⓐ	0.114%	N19978	002	SEP 03, 1992	JUN	DISC
>D>			0.23%	N19978	003	SEP 03, 1992	JUN	DISC
>A>		ⓐ	0.23%	N19978	003	SEP 03, 1992	JUN	DISC
		BUPIVACINE HCL PRESERVATIVE FREE						
	AP	INTL MEDICATED	0.25%	N76012	001	JAN 09, 2002	JAN	NEWA
	AP		0.5%	N76012	002	JAN 09, 2002	JAN	NEWA
	AP		0.75%	N76012	003	JAN 09, 2002	JAN	NEWA

BUSPIRONE HYDROCHLORIDE

>D>		CAPSULE; ORAL						
>D>		BUSPAR						
>D>		BRISTOL MYERS SQUIBB	5MG	N21190	001	DEC 20, 2000	JUN	DISC
>A>		ⓐ	5MG	N21190	001	DEC 20, 2000	JUN	DISC
>D>			7.5MG	N21190	002	DEC 20, 2000	JUN	DISC
>A>		ⓐ	7.5MG	N21190	002	DEC 20, 2000	JUN	DISC
>D>			10MG	N21190	003	DEC 20, 2000	JUN	DISC
>A>		ⓐ	10MG	N21190	003	DEC 20, 2000	JUN	DISC
>D>		+	15MG	N21190	004	DEC 20, 2000	JUN	DISC
>A>		ⓐ	15MG	N21190	004	DEC 20, 2000	JUN	DISC
		TABLET; ORAL						
		BUSPIRONE HCL						
	AB	EGIS	5MG	N75119	001	MAR 14, 2002	MAR	NEWA
	AB		10MG	N75119	002	MAR 14, 2002	MAR	NEWA
	AB	GENEVA PHARMS	5MG	N75413	001	MAR 19, 2002	MAR	NEWA
	AB		10MG	N75413	002	MAR 19, 2002	MAR	NEWA
	AB		15MG	N75413	003	MAR 19, 2002	MAR	NEWA
	AB	KV PHARM	5MG	N75572	001	FEB 27, 2002	FEB	NEWA
	AB		10MG	N75572	002	FEB 27, 2002	FEB	NEWA
	AB		15MG	N75572	003	FEB 27, 2002	FEB	NEWA
	AB	MYLAN	5MG	N75272	001	MAR 01, 2002	MAR	NEWA
	AB		10MG	N75272	002	MAR 01, 2002	MAR	NEWA
	AB		30MG	N76008	001	JUN 28, 2001	MAY	CAHN
	AB	PAR PHARM	5MG	N75467	001	FEB 28, 2002	FEB	NEWA
	AB		10MG	N75467	003	FEB 28, 2002	FEB	NEWA
	AB		15MG	N75467	004	FEB 28, 2002	FEB	NEWA
	AB	PHARMEX PRODS	5MG	N75388	001	MAY 09, 2002	MAY	NEWA
	AB		10MG	N75388	002	MAY 09, 2002	MAY	NEWA
	AB		15MG	N75388	003	MAY 09, 2002	MAY	NEWA
	AB	TEVA	5MG	N75022	001	FEB 28, 2002	FEB	NEWA
	AB		10MG	N75022	002	FEB 28, 2002	FEB	NEWA
	AB		15MG	N75022	003	FEB 28, 2002	FEB	NEWA
	AB	TORPHARM	5MG	N75521	001	APR 05, 2002	APR	NEWA
	AB		10MG	N75521	002	APR 05, 2002	APR	NEWA
	AB		15MG	N75521	003	APR 05, 2002	APR	NEWA
	AB	ZENITH GOLDLINE	5MG	N75385	001	MAR 01, 2002	MAR	NEWA
	AB		10MG	N75385	002	MAR 01, 2002	MAR	NEWA

	AB		15MG	N75385 003	MAR 01, 2002	MAR	NEWA
		BUTORPHANOL TARTRATE					
		SPRAY, METERED; NASAL					
		BUTORPHANOL TARTRATE					
	AB	ROXANE	1MG/SPRAY	N75824 001	MAR 12, 2002	MAR	NEWA
		CAFFEINE; ERGOTAMINE TARTRATE					
		TABLET; ORAL					
		ERCATAB					
>D>	AA +	GENEVA PHARMS	100MG;1MG	N84294 001		JUN	CTEC
>A>	+		100MG;1MG	N84294 001		JUN	CTEC
>D>		WIGRAINE					
>D>	AA	ORGANON	100MG;1MG	N86562 001		JUN	DISC
>A>		@	100MG;1MG	N86562 001		JUN	DISC
		CALCIFEDIOL					
>D>		CAPSULE; ORAL					
>D>		CALDEROL					
>D>		ORGANON	0.02MG	N18312 001		JUN	DISC
>A>		@	0.02MG	N18312 001		JUN	DISC
>D>		+	0.05MG	N18312 002		JUN	DISC
>A>		@	0.05MG	N18312 002		JUN	DISC
		CALCIPOTRIENE					
		OINTMENT; TOPICAL					
		DOVONEX					
	+	BRISTOL MYERS SQUIBB	0.005%	N20273 001	DEC 29, 1993	FEB	CAHN
		SOLUTION; TOPICAL					
	+	BRISTOL MYERS SQUIBB	0.005%	N20611 001	MAR 03, 1997	FEB	CAHN
		CAPTOPRIL					
		TABLET; ORAL					
		CAPOTEN					
	AB	PAR PHARM	12.5MG	N18343 005	JAN 17, 1985	MAY	CAHN
	AB		25MG	N18343 002		MAY	CAHN
		@	37.5MG	N18343 006	SEP 17, 1986	MAY	CAHN
	AB		50MG	N18343 001		MAY	CAHN
		@	75MG	N18343 007	JUN 13, 1995	MAY	CAHN
	AB +		100MG	N18343 003		MAY	CAHN
		@	150MG	N18343 004	JUN 13, 1995	MAY	CAHN
		CARBAMAZEPINE					
		SUSPENSION; ORAL					
		CARBAMAZEPINE					
>A>	AB	MORTON GROVE	100MG/5ML	N75714 001	JUN 05, 2002	JUN	NEWA
		TABLET; ORAL					
	AB	APOTEX	200MG	N75948 001	FEB 27, 2002	FEB	NEWA
		CARTEOLOL HYDROCHLORIDE					
		SOLUTION/DROPS; OPHTHALMIC					
		CARTEOLOL HCL					
	AT	NOVEX	1%	N76097 001	FEB 06, 2002	FEB	NEWA

	CEFACLOR						
	TABLET, EXTENDED RELEASE; ORAL						
	CECLOR CD						
>D>	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	JUN	DISC	
>A>	@	EQ 375MG BASE	N50673 001	JUN 28, 1996	JUN	DISC	
	CEFADROXIL/CEFADROXIL HEMIHYDRATE						
	CAPSULE; ORAL						
	DURICEF						
	@ GALEN CHEM	EQ 250MG BASE	N50512 002		MAY	CAHN	
	FOR SUSPENSION; ORAL						
	GALEN CHEM	EQ 125MG BASE/5ML	N50527 002		MAY	CAHN	
		EQ 250MG BASE/5ML	N50527 003		MAY	CAHN	
	+	EQ 500MG BASE/5ML	N50527 001		MAY	CAHN	
	TABLET; ORAL						
AB	+ GALEN CHEM	EQ 1GM BASE	N50528 001		MAY	CAHN	
	CEFAMANDOLE NAFATE						
	INJECTABLE; INJECTION						
	MANDOL						
>D>	+ LILLY	EQ 10GM BASE/VIAL	N50504 004		JUN	DISC	
>A>	@	EQ 10GM BASE/VIAL	N50504 004		JUN	DISC	
	CEFORANIDE						
>D>	INJECTABLE; INJECTION						
>D>	PRECEF						
>D>	+ BRISTOL	500MG/VIAL	N50554 001	MAY 24, 1984	JUN	DISC	
>A>	@	500MG/VIAL	N50554 001	MAY 24, 1984	JUN	DISC	
>D>	+	1GM/VIAL	N50554 002	MAY 24, 1984	JUN	DISC	
>A>	@	1GM/VIAL	N50554 002	MAY 24, 1984	JUN	DISC	
>D>	+	2GM/VIAL	N50554 003	MAY 24, 1984	JUN	DISC	
>A>	@	2GM/VIAL	N50554 003	MAY 24, 1984	JUN	DISC	
>D>	+	10GM/VIAL	N50554 004	MAY 24, 1984	JUN	DISC	
>A>	@	10GM/VIAL	N50554 004	MAY 24, 1984	JUN	DISC	
>D>	+	20GM/VIAL	N50554 005	MAY 24, 1984	JUN	DISC	
>A>	@	20GM/VIAL	N50554 005	MAY 24, 1984	JUN	DISC	
	CEFPODOXIME PROXETIL						
	FOR SUSPENSION; ORAL						
	CEFPODOXIME PROXETIL						
AB	RANBAXY	EQ 50MG BASE/5ML	N65082 001	MAY 31, 2002	MAY	NEWA	
AB		EQ 100MG BASE/5ML	N65082 002	MAY 31, 2002	MAY	NEWA	
	VANTIN						
AB	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992	MAY	CFTG	
AB	+	EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992	MAY	CFTG	
	CEFTRIAXONE SODIUM; LIDOCAINE						
>D>	INJECTABLE; INJECTION						
>D>	ROCEPHIN KIT						
>D>	+ HLR	EQ 1GM BASE/VIAL;1%	N50585 006	MAY 08, 1996	JUN	DISC	
>D>	+	EQ 500MG BASE/VIAL;1%	N50585 007	MAY 08, 1996	JUN	DISC	
>A>	@	EQ 500MG BASE/VIAL;1%	N50585 007	MAY 08, 1996	JUN	DISC	

>A>		@	EQ 1GM BASE/VIAL;1%	N50585	006	MAY 08, 1996	JUN	DISC
		CEFUROXIME AXETIL						
		TABLET; ORAL						
		CEFTIN						
	AB	GLAXOSMITHKLINE	EQ 125MG BASE	N50605	001	DEC 28, 1987	FEB	CFTG
	AB		EQ 250MG BASE	N50605	002	DEC 28, 1987	FEB	CFTG
	AB	+	EQ 500MG BASE	N50605	003	DEC 28, 1987	FEB	CFTG
		CEFUROXIME AXETIL						
	AB	RANBAXY	EQ 125MG BASE	N65043	003	FEB 15, 2002	FEB	NEWA
	AB		EQ 250MG BASE	N65043	002	FEB 15, 2002	FEB	NEWA
	AB		EQ 500MG BASE	N65043	001	FEB 15, 2002	FEB	NEWA
		CEPHALEXIN						
		FOR SUSPENSION; ORAL						
		CEPHALEXIN						
		@ TEVA	EQ 125MG BASE/5ML	N62873	001	MAY 23, 1988	APR	DISC
		@	EQ 250MG BASE/5ML	N62867	001	APR 15, 1988	APR	DISC
		TABLET; ORAL						
>D>	AB	TEVA	EQ 500MG BASE	N63024	001	JAN 12, 1989	JUN	CTEC
>A>			EQ 500MG BASE	N63024	001	JAN 12, 1989	JUN	CTEC
		KEFLET						
>D>	AB	+ LILLY	EQ 500MG BASE	N50440	001		JUN	DISC
>A>		@	EQ 500MG BASE	N50440	001		JUN	DISC
		CEPHALOGLYCIN						
		CAPSULE; ORAL						
		KAFOCIN						
		+ @ LILLY	250MG	N50219	001		MAY	DISC
		CEPHALOTHIN SODIUM						
		INJECTABLE; INJECTION						
		KEFLIN						
>D>		+ LILLY	EQ 20GM BASE/VIAL	N50482	007		JUN	DISC
>A>		@	EQ 20GM BASE/VIAL	N50482	007		JUN	DISC
		CEPHAPIRIN SODIUM						
		INJECTABLE; INJECTION						
		CEFADYL						
>D>		APOTHECON	EQ 500MG BASE/VIAL	N62961	001	SEP 20, 1988	JUN	DISC
>A>			EQ 500MG BASE/VIAL	N62961	001	SEP 20, 1988	JUN	DISC
>D>			EQ 1GM BASE/VIAL	N62961	002	SEP 20, 1988	JUN	DISC
>A>		@	EQ 1GM BASE/VIAL	N62961	002	SEP 20, 1988	JUN	DISC
>D>			EQ 2GM BASE/VIAL	N62961	003	SEP 20, 1988	JUN	DISC
>A>		@	EQ 2GM BASE/VIAL	N62961	003	SEP 20, 1988	JUN	DISC
>D>			EQ 4GM BASE/VIAL	N62961	004	SEP 20, 1988	JUN	DISC
>A>		@	EQ 4GM BASE/VIAL	N62961	004	SEP 20, 1988	JUN	DISC
		CERIVASTATIN SODIUM						
		TABLET; ORAL						
		BAYCOL						
		@ BAYER	0.2MG	N20740	003	JUN 26, 1997	JAN	DISC
		@	0.3MG	N20740	004	JUN 26, 1997	JAN	DISC

	@	0.4MG	N20740 005	MAY 24, 1999	JAN	DISC
	@	0.8MG	N20740 006	JUL 24, 2000	JAN	DISC
	CHLORAMPHENICOL PALMITATE					
>D>	SUSPENSION; ORAL					
>D>	CHLOROMYCETIN PALMITATE					
>D>	+ PARKE DAVIS	EQ 150MG BASE/5ML	N50152 001		JUN	DISC
>A>	@	EQ 150MG BASE/5ML	N50152 001		JUN	DISC
	CHLORMEZANONE					
>D>	TABLET; ORAL					
>D>	TRANCOPAL					
>D>	+ SANOFI SYNTHELABO	100MG	N11467 003		JUN	DISC
>A>	@	100MG	N11467 003		JUN	DISC
>D>	+	200MG	N11467 005		JUN	DISC
>A>	@	200MG	N11467 005		JUN	DISC
	CHLORPHENESIN CARBAMATE					
>D>	TABLET; ORAL					
>D>	MAOLATE					
>D>	+ PHARMACIA AND UPJOHN	400MG	N14217 002		JUN	DISC
>A>	@	400MG	N14217 002		JUN	DISC
	CHLORPROMAZINE HYDROCHLORIDE					
	CAPSULE, EXTENDED RELEASE; ORAL					
	THORAZINE					
>D>	+ GLAXOSMITHKLINE	30MG	N11120 016		JUN	DISC
>A>	@	30MG	N11120 016		JUN	DISC
>D>	+	75MG	N11120 017		JUN	DISC
>A>	@	75MG	N11120 017		JUN	DISC
>D>	+	150MG	N11120 018		JUN	DISC
>A>	@	150MG	N11120 018		JUN	DISC
	CHLORPROPAMIDE					
	TABLET; ORAL					
	CHLORPROPAMIDE					
	@ LEDERLE	100MG	N89561 001	SEP 04, 1987	MAY	DISC
	@	250MG	N89562 001	SEP 04, 1987	MAY	DISC
	CHLORTETRACYCLINE HYDROCHLORIDE					
>D>	OINTMENT; OPHTHALMIC					
>D>	AUREOMYCIN					
>D>	+ LEDERLE	1%	N50404 001		JUN	DISC
>A>	@	1%	N50404 001		JUN	DISC
	CHOLESTYRAMINE					
>D>	TABLET; ORAL					
>D>	QUESTRAN					
>D>	+ APOTHECON	EQ 800MG RESIN	N73403 002	DEC 27, 1999	JUN	DISC
>A>	@	EQ 800MG RESIN	N73403 002	DEC 27, 1999	JUN	DISC

CHORIOGONADOTROPIN ALFA
INJECTABLE; INJECTION
OVIDREL
+ SERONO INC 0.25MG/VIAL N21149 001 SEP 20, 2000 FEB CAHN

CHYMOPAPAIN
INJECTABLE; INJECTION
CHYMODIACTIN
>D> + ABBOTT 4,000 UNITS/VIAL N18663 002 AUG 21, 1984 JUN DISC
>A> @ 4,000 UNITS/VIAL N18663 002 AUG 21, 1984 JUN DISC

CHYMOTRYPSIN
>D> FOR SOLUTION; OPHTHALMIC
>D> ZOLYSE
>D> + ALCON 750 UNITS/VIAL N11903 001 JUN DISC
>A> @ 750 UNITS/VIAL N11903 001 JUN DISC

CICLOPIROX
SOLUTION; TOPICAL
PENLAC
>D> + AVENTIS PHARMS 8% N21022 001 DEC 17, 1999 JUN CAHN
>A> + DERMIK LABS 8% N21022 001 DEC 17, 1999 JUN CAHN

CIMETIDINE
TABLET; ORAL
CIMETIDINE
AB LEK LJUBLJANA 300MG N74250 002 JUN 29, 1995 FEB CMFD
AB 400MG N74250 003 JUN 29, 1995 FEB CMFD
AB 800MG N74250 004 JUN 29, 1995 FEB CMFD

CINOXACIN
>D> CAPSULE; ORAL
>D> CINOBAC
>D> LILLY 250MG N18067 001 JUN DISC
>A> @ 250MG N18067 001 JUN DISC
>D> + 500MG N18067 002 JUN DISC
>A> @ 500MG N18067 002 JUN DISC

CLADRIBINE
INJECTABLE; INJECTION
LEUSTATIN
+ ORTHO BIOTECH 1MG/ML N20229 001 FEB 26, 1993 MAR CAHN

CLARITHROMYCIN
FOR SUSPENSION; ORAL
BIAXIN
>D> ABBOTT 187MG/5ML N50698 003 SEP 30, 1998 JUN DISC
>A> @ 187MG/5ML N50698 003 SEP 30, 1998 JUN DISC

CLINDAMYCIN PHOSPHATE
LOTION; TOPICAL
CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	EQ 1% BASE	N50600 001	MAY 31, 1989	JAN	CFTG
		CLINDAMYCIN PHOSPHATE					
AB		ALTANA	EQ 1% BASE	N65067 001	JAN 31, 2002	JAN	NEWA
		SWAB; TOPICAL					
AT		CLAY PARK	EQ 1% BASE	N65049 001	MAY 25, 2000	FEB	CDFR

CLOBETASOL PROPIONATE
GEL; TOPICAL
EMBELINE

AB		HEALTHPOINT	0.05%	N76141 001	APR 12, 2002	APR	NEWA

CLOFAZIMINE

>D>		CAPSULE; ORAL						
>D>		LAMPRENE						
>D>		+ NOVARTIS	100MG	N19500 001	DEC 15, 1986	JUN	DISC
>A>		@	100MG	N19500 001	DEC 15, 1986	JUN	DISC

CLONAZEPAM
TABLET; ORAL
KLONOPIN

>D>		+ ROCHE	0.125MG	N17533 005	APR 09, 1997	JUN	DISC
>A>		@	0.125MG	N17533 005	APR 09, 1997	JUN	DISC
>D>			0.25MG	N17533 006	APR 09, 1997	JUN	DISC
>A>		@	0.25MG	N17533 006	APR 09, 1997	JUN	DISC
>D>		TABLET, ORALLY DISINTEGRATING; ORAL						
>D>		KLONOPIN RAPIDLY DISINTEGRATING						
>D>		+ ROCHE	0.125MG	N20813 001	DEC 23, 1997	JUN	DISC
>A>		@	0.125MG	N20813 001	DEC 23, 1997	JUN	DISC
>D>			0.25MG	N20813 002	DEC 23, 1997	JUN	DISC
>A>		@	0.25MG	N20813 002	DEC 23, 1997	JUN	DISC
>D>			0.5MG	N20813 003	DEC 23, 1997	JUN	DISC
>A>		@	0.5MG	N20813 003	DEC 23, 1997	JUN	DISC
>D>		+	1MG	N20813 004	DEC 23, 1997	JUN	DISC
>A>		@	1MG	N20813 004	DEC 23, 1997	JUN	DISC
>D>			2MG	N20813 005	DEC 23, 1997	JUN	DISC
>A>		@	2MG	N20813 005	DEC 23, 1997	JUN	DISC

CLOZAPINE
TABLET; ORAL
CLOZARIL

AB		NOVARTIS	25MG	N19758 001	SEP 26, 1989	MAY	CRLD
AB	+		100MG	N19758 002	SEP 26, 1989	MAY	CRLD

COLCHICINE; PROBENECID
TABLET; ORAL
COL-PROBENECID

>D>	BP	WATSON LABS	0.5MG;500MG	N84279 001		JUN	CRLD
>A>	BP +		0.5MG;500MG	N84279 001		JUN	CRLD
		COLBENEMID						

		COLCHICINE; PROBENECID						
>D>		TABLET; ORAL						
>D>		COLBENEMID						
>D>	BP +	MERCK	0.5MG;500MG	N12383 001		JUN	DISC	
>A>		@	0.5MG;500MG	N12383 001		JUN	DISC	
		COLESEVELAM HYDROCHLORIDE						
>D>		CAPSULE; ORAL						
>D>		WELCHOL						
>D>	+	SANKYO	375MG	N21141 001	MAY 26, 2000	JUN	DISC	
>A>		@	375MG	N21141 001	MAY 26, 2000	JUN	DISC	
		CORTISONE ACETATE						
>D>		INJECTABLE; INJECTION						
>D>		CORTONE						
>D>		MERCK	25MG/ML	N07110 002		JUN	DISC	
>A>		@	25MG/ML	N07110 002		JUN	DISC	
>D>	+		50MG/ML	N07110 003		JUN	DISC	
>A>		@	50MG/ML	N07110 003		JUN	DISC	
		CROMOLYN SODIUM						
		SOLUTION; INHALATION						
		CROMOLYN SODIUM						
	AN	NOVEX	10MG/ML	N75333 001	APR 30, 2002	APR	NEWA	
		CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58						
		N/A; N/A						
		DICOPAC KIT						
		@ AMERSHAM HLTH	N/A;N/A;N/A	N17406 001		FEB	DISC	
		CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR						
>D>		N/A; N/A						
>D>		CYANOCOBALAMIN CO 57 SCHILLING TEST KIT						
>D>		MALLINCKRODT	0.1MG;0.5uCi;60MG	N16635 001		JUN	DISC	
>A>		@	0.1MG;0.5uCi;60MG	N16635 001		JUN	DISC	
		CYCLOBENZAPRINE HYDROCHLORIDE						
		TABLET; ORAL						
		FLEXERIL						
>A>		@ MCNEIL CONS SPECLT	5MG	N17821 001		JUN	CAHN	
>A>	AB +		10MG	N17821 002		JUN	CAHN	
>D>		@ MERCK	5MG	N17821 001		JUN	CAHN	
>D>	AB +		10MG	N17821 002		JUN	CAHN	
		CYCLOPHOSPHAMIDE						
		INJECTABLE; INJECTION						
		CYCLOPHOSPHAMIDE						
>D>	AP	ASTA	100MG/VIAL	N88371 001	JUL 03, 1986	JUN	CAHN	
>D>	AP		200MG/VIAL	N88372 001	JUL 03, 1986	JUN	CAHN	
>D>	AP		500MG/VIAL	N88373 001	JUL 03, 1986	JUN	CAHN	
>D>	AP		1GM/VIAL	N88374 001	SEP 24, 1986	JUN	CAHN	
>A>	AP	BAXTER HLTHCARE	100MG/VIAL	N88371 001	JUL 03, 1986	JUN	CAHN	
>A>	AP		200MG/VIAL	N88372 001	JUL 03, 1986	JUN	CAHN	

>A>	AP	500MG/VIAL	N88373 001	JUL 03, 1986	JUN	CAHN
>A>	AP	1GM/VIAL	N88374 001	SEP 24, 1986	JUN	CAHN
	CYCLOSPORINE					
	CAPSULE; ORAL					
	CYCLOSPORINE					
	AB1 ABBOTT	25MG	N65003 001	MAY 12, 2000	MAY	CTEC
	BX	50MG	N65003 002	MAY 12, 2000	MAY	CTEC
	AB1	100MG	N65003 003	MAY 12, 2000	MAY	CTEC
	AB1 EON	25MG	N65017 002	JAN 13, 2000	MAY	CTEC
	AB1	100MG	N65017 001	JAN 13, 2000	MAY	CTEC
	AB1 SIDMAK LABS	25MG	N65044 002	DEC 20, 2000	MAY	CTEC
	AB1	100MG	N65044 001	DEC 20, 2000	MAY	CTEC
	AB2 TORPHARM	25MG	N65040 001	MAY 09, 2002	MAY	CTEC
	AB2	100MG	N65040 002	MAY 09, 2002	MAY	NEWA
	NEORAL					
	AB1 NOVARTIS	25MG	N50715 001	JUL 14, 1995	MAY	CTEC
	AB1 +	100MG	N50715 002	JUL 14, 1995	MAY	CTEC
	SANDIMMUNE					
	AB2 NOVARTIS	25MG	N50625 001	MAR 02, 1990	MAY	CTEC
	AB2 +	100MG	N50625 002	MAR 02, 1990	MAY	CTEC
	SOLUTION; ORAL					
	CYCLOSPORINE					
	AB ABBOTT	100MG/ML	N65025 001	MAR 03, 2000	JAN	CMFD
	DALFOPRISTIN; QUINUPRISTIN					
>D>	INJECTABLE; IV (INFUSION)					
>D>	SYNERCID					
>D>	AVENTIS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	JUN	CRLD
>A>	+	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	JUN	CRLD
>D>	+	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	JUN	DISC
>A>	@	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	JUN	DISC
	DANAPAROID SODIUM					
	INJECTABLE; INJECTION					
	ORGARAN					
>D>	+ ORGANON	750 UNITS/0.6ML	N20430 001	DEC 24, 1996	JUN	DISC
>A>	@	750 UNITS/0.6ML	N20430 001	DEC 24, 1996	JUN	DISC
	DEFEROXAMINE MESYLATE					
	INJECTABLE; INJECTION					
	DESFERAL					
	+ NOVARTIS	2GM/VIAL	N16267 002	MAY 25, 2000	FEB	CPOT
	DEMECARIUM BROMIDE					
>D>	SOLUTION/DROPS; OPHTHALMIC					
>D>	HUMORSOL					
>D>	+ MERCK	0.125%	N11860 002		JUN	DISC
>A>	@	0.125%	N11860 002		JUN	DISC
>D>	+	0.25%	N11860 001		JUN	DISC
>A>	@	0.25%	N11860 001		JUN	DISC

DEMECLOCYCLINE HYDROCHLORIDE
TABLET; ORAL
DECLOMYCIN
>D> LEDERLE 75MG N50261 001 JUN DISC
>A> @ 75MG N50261 001 JUN DISC

DESLORATADINE
>A> TABLET, ORALLY DISINTEGRATING; ORAL
>A> CLARINEX
>A> + SCHERING 5MG N21312 001 JUN 26, 2002 JUN NEWA

DESMOPRESSIN ACETATE
SOLUTION; NASAL
>D> CONCENTRAID
>D> BX FERRING 0.01% N19776 001 DEC 26, 1990 JUN DISC
>A> @ 0.01% N19776 001 DEC 26, 1990 JUN DISC
SPRAY, METERED; NASAL
DDAVP
@ AVENTIS 0.01MG/SPRAY N17922 002 FEB 06, 1989 MAY DISC
DESMOPRESSIN ACETATE
AB + BAUSCH AND LOMB 0.01MG/SPRAY N74830 001 JAN 25, 1999 MAY CRLD

DESOGESTREL; ETHINYL ESTRADIOL
TABLET; ORAL-28
KARIVA
AB BARR 0.15MG;0.02MG;0.01MG N75863 001 APR 05, 2002 APR NEWA
MIRCETTE
AB + ORGANON 0.15MG;0.02MG;0.01MG N20713 001 APR 22, 1998 APR CFTG

DESONIDE
LOTION; TOPICAL
DESONIDE
AB ALTANA 0.05% N75860 001 MAR 19, 2002 MAR NEWA
DESOWEN
AB + GALDERMA LABS LP 0.05% N72354 001 JAN 24, 1992 MAR CFTG

DESOXIMETASONE
OINTMENT; TOPICAL
DESOXIMETASONE
@ ALTANA 0.25% N73440 001 APR 01, 1998 MAY DISC

DEXAMETHASONE
>D> AEROSOL; TOPICAL
>D> DECASPRAY
>D> + MERCK 0.04% N12731 002 JUN DISC
>A> @ 0.04% N12731 002 JUN DISC

DEXAMETHASONE ACETATE
INJECTABLE; INJECTION
DECADRON-LA
@ MERCK EQ 8MG BASE/ML N16675 001 APR DISC
DEXAMETHASONE ACETATE

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DEXAMETHASONE ACETATE

	@ STERIS	EQ 8MG BASE/ML	N84315 001			APR	DISC
	@	EQ 16MG BASE/ML	N87711 001	MAY 24, 1982		APR	DISC

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

MAXIDEX

>D>	+ ALCON	EQ 0.05% PHOSPHATE	N83342 001			JUN	DISC
>A>	@	EQ 0.05% PHOSPHATE	N83342 001			JUN	DISC

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

>D>	+ MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N13334 002			JUN	DISC
>A>	@	EQ 4MG PHOSPHATE/ML;10MG/ML	N13334 002			JUN	DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	+ GLAXOSMITHKLINE	5MG	N17078 001			JAN	CFTG
AB	+	10MG	N17078 002			JAN	CFTG
AB	+	15MG	N17078 003			JAN	CFTG

DEXTROAMPHETAMINE SULFATE

AB	BARR	5MG	N76137 001	JAN 18, 2002		JAN	NEWA
AB		10MG	N76137 002	JAN 18, 2002		JAN	NEWA
AB		15MG	N76137 003	JAN 18, 2002		JAN	NEWA

TABLET; ORAL

AA	MALLINCKRODT	5MG	N40436 001	JAN 29, 2002		JAN	NEWA
AA		10MG	N40436 002	JAN 29, 2002		JAN	NEWA

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE

>D>	+ BRACCO	76%	N10040 017			JUN	DISC
>A>	@	76%	N10040 017			JUN	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOVIST

>D>	+ BRACCO	34.3%;35%	N10040 020			JUN	DISC
>A>	@	34.3%;35%	N10040 020			JUN	DISC

RENOVIST II

>D>	+ BRACCO	28.5%;29.1%	N10040 019			JUN	DISC
>A>	@	28.5%;29.1%	N10040 019			JUN	DISC

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE

>D>	+ AMERSHAM HLTH	25%	N09561 003			JUN	DISC
>A>	@	25%	N09561 003			JUN	DISC

SOLUTION; URETERAL

DIATRIZOATE SODIUM

>D>		SOLUTION; URETERAL					
>D>		HYPAQUE SODIUM 20%					
>D>	+	AMERSHAM HLTH	20%	N09561 002		JUN	DISC
>A>		@	20%	N09561 002		JUN	DISC

DIAZOXIDE

>D>		CAPSULE; ORAL					
>D>		PROGLYCEM					
>D>	+	BAKER NORTON	50MG	N17425 001		JUN	DISC
>A>		@	50MG	N17425 001		JUN	DISC

DICLOFENAC POTASSIUM

		TABLET; ORAL					
		DICLOFENAC POTASSIUM					
AB		MUTUAL PHARM	50MG	N75470 001	FEB 21, 2002	FEB	NEWA

DICLOFENAC SODIUM

		TABLET, DELAYED RELEASE; ORAL					
		DICLOFENAC SODIUM					
AB		ALPHAPHARM	50MG	N75281 002	FEB 12, 2002	FEB	NEWA
AB			75MG	N75281 003	FEB 12, 2002	FEB	NEWA
		TABLET, EXTENDED RELEASE; ORAL					
AB		PUREPAC PHARM	100MG	N75910 001	JAN 07, 2002	JAN	NEWA

DICUMAROL

>D>		TABLET; ORAL					
>D>		DICUMAROL					
>D>	+	ABBOTT	25MG	N05545 003		JUN	DISC
>A>		@	25MG	N05545 003		JUN	DISC

DIENESTROL

		CREAM; VAGINAL					
		DIENESTROL					
>D>	+	JOHNSON RW	0.01%	N06110 005		JUN	CAHN
>A>	+	ORTHO MCNEIL	0.01%	N06110 005		JUN	CAHN

DIHYDROERGOTAMINE MESYLATE

		INJECTABLE; INJECTION					
		D.H.E. 45					
>D>	+	NOVARTIS	1MG/ML	N05929 001		JUN	CAHN
>A>		XCEL PHARMS	1MG/ML	N05929 001		JUN	CAHN

DILTIAZEM HYDROCHLORIDE

		INJECTABLE; INJECTION					
		CARDIZEM					
>D>	AP +	AVENTIS PHARMS	5MG/ML	N20027 001	OCT 24, 1991	JUN	CAHN
>D>	+		25MG/VIAL	N20027 003	AUG 18, 1995	JUN	CAHN
>A>	AP +	BIOVAIL	5MG/ML	N20027 001	OCT 24, 1991	JUN	CAHN
>A>	+		25MG/VIAL	N20027 003	AUG 18, 1995	JUN	CAHN
		DILTIAZEM HCL					
	+	GENSIA SICOR PHARMS	10MG/ML	N74894 002	APR 19, 2002	APR	NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE
TABLET, EXTENDED RELEASE; ORAL
TECZEM

>A>	+	BIOVAIL	EQ 180MG HCL;5MG	N20507	001	OCT 04, 1996	JUN	CAHN
>D>	+	MERCK	EQ 180MG HCL;5MG	N20507	001	OCT 04, 1996	JUN	CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE
INJECTABLE; INTRAVENOUS
IMAGENT

	+	ALLIANCE PHARM	0.92MG/VIAL;0.092MG/VIAL	N21191	001	MAY 31, 2002	MAY	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

AP		AM PHARM PARTNERS	50MG/ML	N40466	001	MAY 28, 2002	MAY	NEWA

DIPHENIDOL HYDROCHLORIDE
TABLET; ORAL
VONTROL

>D>	+	GLAXOSMITHKLINE	EQ 25MG BASE	N16033	001		JUN	DISC
>A>		@	EQ 25MG BASE	N16033	001		JUN	DISC

DONEPEZIL HYDROCHLORIDE
TABLET; ORAL
ARICEPT

		EISAI MEDCL RES	5MG	N20690	002	NOV 25, 1996	MAY	CAHN
	+		10MG	N20690	001	NOV 25, 1996	MAY	CAHN

DOXEPIN HYDROCHLORIDE
CAPSULE; ORAL
DOXEPIN HCL

	@	LEDERLE	EQ 10MG BASE	N71685	001	JAN 05, 1988	MAY	DISC
	@		EQ 25MG BASE	N71686	001	JAN 05, 1988	MAY	DISC
	@		EQ 50MG BASE	N71673	001	JAN 05, 1988	MAY	DISC
	@		EQ 75MG BASE	N71674	001	JAN 05, 1988	MAY	DISC
	@		EQ 100MG BASE	N71675	001	JAN 05, 1988	MAY	DISC
	@		EQ 150MG BASE	N71676	001	JAN 05, 1988	MAY	DISC

CREAM; TOPICAL
ZONALON

>D>	+	BIOGLAN PHARMA	5%	N20126	001	APR 01, 1994	JUN	CAHN
>A>	+	BIOGLAN PHARMS	5%	N20126	001	APR 01, 1994	JUN	CAHN

DOXYCYCLINE HYCLATE
CAPSULE; ORAL
PERIOSTAT

>D>	+	COLLAGENEX	EQ 20MG BASE	N50744	001	SEP 30, 1998	JUN	DISC
>A>		@	EQ 20MG BASE	N50744	001	SEP 30, 1998	JUN	DISC

DROPERIDOL; FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

>D>	AP +	ABBOTT	2.5MG/ML;EQ 0.05MG BASE/ML	N71982	001	MAY 04, 1988	JUN	CTEC

>A>	+		2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	MAY 04, 1988	JUN	CTEC
>D>	AP	ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72026 001	APR 13, 1989	JUN	DISC
>A>		@	2.5MG/ML;EQ 0.05MG BASE/ML	N72026 001	APR 13, 1989	JUN	DISC
		ECHOTHIOPHATE IODIDE					
		FOR SOLUTION; OPHTHALMIC					
		PHOSPHOLINE IODIDE					
>D>		+ AYERST	0.03%	N11963 002		JUN	DISC
>A>		@	0.03%	N11963 002		JUN	DISC
>D>		+	0.06%	N11963 004		JUN	DISC
>A>		@	0.06%	N11963 004		JUN	DISC
>D>		+	0.25%	N11963 003		JUN	DISC
>A>		@	0.25%	N11963 003		JUN	DISC
		EFAVIRENZ					
		TABLET; ORAL					
		SUSTIVA					
		BRISTOL MYERS SQUIBB	300MG	N21360 001	FEB 01, 2002	FEB	NEWA
		+	600MG	N21360 002	FEB 01, 2002	FEB	NEWA
		ENALAPRIL MALEATE					
		TABLET; ORAL					
		VASOTEC					
	AB	BIOVAIL	2.5MG	N18998 005	JUL 26, 1988	MAY	CAHN
	AB		5MG	N18998 001	DEC 24, 1985	MAY	CAHN
	AB		10MG	N18998 002	DEC 24, 1985	MAY	CAHN
	AB	+	20MG	N18998 003	DEC 24, 1985	MAY	CAHN
		ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE					
		TABLET; ORAL					
		VASERETIC					
	AB	BIOVAIL	5MG;12.5MG	N19221 003	JUL 12, 1995	MAY	CAHN
	AB	+	10MG;25MG	N19221 001	OCT 31, 1986	MAY	CAHN
		ENALAPRILAT					
		INJECTABLE; INJECTION					
		VASOTEC					
	AP	+ BIOVAIL	1.25MG/ML	N19309 001	FEB 09, 1988	MAY	CAHN
		ENOXACIN					
>D>		TABLET; ORAL					
>D>		PENETREX					
>D>		AVENTIS	200MG	N19616 004	DEC 31, 1991	JUN	DISC
>A>		@	200MG	N19616 004	DEC 31, 1991	JUN	DISC
>D>		+	400MG	N19616 005	DEC 31, 1991	JUN	DISC
>A>		@	400MG	N19616 005	DEC 31, 1991	JUN	DISC
		ENOXAPARIN SODIUM					
		INJECTABLE; SUBCUTANEOUS					
		LOVENOX					
>D>		+ AVENTIS	90MG/0.6ML	N20164 006	JUN 02, 2000	JUN	DISC
>A>		@	90MG/0.6ML	N20164 006	JUN 02, 2000	JUN	DISC

	EPINEPHRINE						
>D>	INJECTABLE; INJECTION						
>D>	SUS-PHRINE SULFITE-FREE						
>D>	FORREST LABS	1.5MG/AMP	N07942 003	FEB 05, 1999	JUN	DISC	
>A>	@	1.5MG/AMP	N07942 003	FEB 05, 1999	JUN	DISC	
>D>	+	5MG/ML	N07942 001		JUN	DISC	
>A>	@	5MG/ML	N07942 001		JUN	DISC	
	INJECTABLE; INTRAMUSCULAR						
>D>	EPI E Z PEN JR						
>D>	+ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 004	AUG 03, 1995	JUN	DISC	
>A>	@	0.15MG/DELIVERY	N19430 004	AUG 03, 1995	JUN	DISC	
>D>	EPIPEN E Z PEN						
>D>	+ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 003	AUG 03, 1995	JUN	DISC	
>A>	@	0.3MG/DELIVERY	N19430 003	AUG 03, 1995	JUN	DISC	
	EPROSARTAN MESYLATE						
	TABLET; ORAL						
	TEVETEN						
>A>	BIOVAIL PHARMS	EQ 300MG BASE	N20738 004	DEC 22, 1997	JUN	CAHN	
>A>		EQ 400MG BASE	N20738 005	DEC 22, 1997	JUN	CAHN	
>A>	+	EQ 600MG BASE	N20738 006	MAY 27, 1999	JUN	CAHN	
>D>	UNIMED PHARMS	EQ 300MG BASE	N20738 004	DEC 22, 1997	JUN	CAHN	
>D>		EQ 400MG BASE	N20738 005	DEC 22, 1997	JUN	CAHN	
>D>	+	EQ 600MG BASE	N20738 006	MAY 27, 1999	JUN	CAHN	
	EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE						
	TABLET; ORAL						
	TEVETEN HCT						
>A>	BIOVAIL PHARMS	600MG;12.5MG	N21268 001	NOV 01, 2001	JUN	CAHN	
>A>	+	600MG;25MG	N21268 002	NOV 01, 2001	JUN	CAHN	
>D>	UNIMED PHARMS	600MG;12.5MG	N21268 001	NOV 01, 2001	JUN	CAHN	
>D>	+	600MG;25MG	N21268 002	NOV 01, 2001	JUN	CAHN	
	EPTIFIBATIDE						
	INJECTABLE; INJECTION						
	INTEGRILIN						
	+ MILLENNIUM PHARMS	2MG/ML	N20718 001	MAY 18, 1998	FEB	CAHN	
	+	75MG/100ML	N20718 002	MAY 18, 1998	FEB	CAHN	
	ERGOLOID MESYLATES						
>D>	CAPSULE; ORAL						
>D>	HYDERGINE LC						
>D>	+ NOVARTIS	1MG	N18706 001	JAN 18, 1983	JUN	DISC	
>A>	@	1MG	N18706 001	JAN 18, 1983	JUN	DISC	
>D>	SOLUTION; ORAL						
>D>	HYDERGINE						
>D>	NOVARTIS	1MG/ML	N18418 001		JUN	DISC	
>A>	@	1MG/ML	N18418 001		JUN	DISC	

ERYTHROMYCIN
GEL; TOPICAL
E-GLADES

AT	GLADES PHARMS	2%	N65009 001	MAR 18, 2002	MAR	NEWA

ESTRADIOL
FILM, EXTENDED RELEASE; TRANSDERMAL
ALORA

BX	WATSON LABS	0.025MG/24HR	N20655 004	APR 16, 2002	APR	NEWA
BX		0.025MG/24HR	N20655 004	APR 05, 2002	MAY	CMS1

TABLET; ORAL
ESTRADIOL

AB	USL PHARMA	0.5MG	N40297 001	APR 17, 2002	APR	NEWA
AB		1MG	N40297 002	APR 17, 2002	APR	NEWA
AB		2MG	N40297 003	APR 17, 2002	APR	NEWA

ESTRADIOL; NORETHINDRONE ACETATE
TABLET; ORAL
ACTIVELLA

>D>	+ NOVO NORDISK	1MG;0.5MG	N20907 001	NOV 18, 1998	JUN	CTNA
>A>	+	1MG;0.5MG	N20907 001	NOV 18, 1998	JUN	CTNA

ESTRADIOL; NORGESTIMATE
TABLET; ORAL
ORTHO-PREFEST

	+ KING PHARMS	1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28

>D>	PREMPHASE (PREMARIN;CYCRIN 14/14)						
>D>	+ WYETH AYERST	0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	JUN	DISC
>A>	@	0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	JUN	DISC
>D>	PREMPRO (PREMARIN;CYCRIN)						
>D>	+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JUN	DISC
>A>	@	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JUN	DISC

ESTROGENS, CONJUGATED; MEPROBAMATE
TABLET; ORAL

>D>	PMB 200						
>D>	+ WYETH AYERST	0.45MG;200MG	N10971 005		JUN	DISC
>A>	@	0.45MG;200MG	N10971 005		JUN	DISC
>D>	PMB 400						
>D>	+ WYETH AYERST	0.45MG;400MG	N10971 003		JUN	DISC
>A>	@	0.45MG;400MG	N10971 003		JUN	DISC

ETHCHLORVYNOL
CAPSULE; ORAL

>D>	PLACIDYL						
>D>	+ ABBOTT	200MG	N10021 007		JUN	DISC
>A>	@	200MG	N10021 007		JUN	DISC
>D>	+	500MG	N10021 002		JUN	DISC
>A>	@	500MG	N10021 002		JUN	DISC

>D>	+		750MG	N10021 010			JUN	DISC
>A>	@		750MG	N10021 010			JUN	DISC
	ETHINYL ESTRADIOL; LEVONORGESTREL							
	TABLET; ORAL-21							
	ALESSE							
AB	+	WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997		MAR	CTEC
AB1	+		0.02MG;0.1MG	N20683 001	MAR 27, 1997		MAY	CTEC
	AVIANE-21							
AB1		DURAMED PHARM BARR	0.02MG;0.1MG	N75796 002	APR 30, 2001		MAR	CTEC
	LESSINA-21							
AB2		BARR	0.02MG;0.1MG	N75803 001	MAR 20, 2002		MAR	NEWA
	LEVLITE							
AB2	+	BERLEX LABS	0.02MG;0.1MG	N20860 001	JUL 13, 1998		MAR	CTEC
	PORTIA-21							
AB		BARR	0.03MG;0.15MG	N75866 001	MAY 23, 2002		MAY	NEWA
	TABLET; ORAL-28							
	ALESSE							
AB1		WYETH AYERST	0.02MG;0.1MG	N20683 002	MAR 27, 1997		MAR	CTEC
	AVIANE-28							
AB1		DURAMED PHARM BARR	0.02MG;0.1MG	N75796 001	APR 30, 2001		MAR	CTEC
	LESSINA-28							
AB		BARR	0.02MG;0.1MG	N75803 002	MAR 20, 2002		MAR	NEWA
	LEVLITE							
AB		BERLEX LABS	0.02MG;0.1MG	N20860 002	JUL 13, 1998		MAR	CTEC
	PORTIA-28							
AB		BARR	0.03MG;0.15MG	N75866 002	MAY 23, 2002		MAY	NEWA
	ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
>D>	TABLET; ORAL-21							
>D>	ESTROSTEP 21							
>D>	+	PARKE DAVIS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130 001	OCT 09, 1996		JUN	DISC
>A>	@		0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N20130 001	OCT 09, 1996		JUN	DISC
	ETHOTOIN							
	TABLET; ORAL							
	PEGANONE							
>D>		ABBOTT	250MG	N10841 001			JUN	CRLD
>A>	+		250MG	N10841 001			JUN	CRLD
>D>	+		500MG	N10841 003			JUN	DISC
>A>	@		500MG	N10841 003			JUN	DISC
	FAMOTIDINE							
	INJECTABLE; INJECTION							
	FAMOTIDINE							
AP		BAXTER HLTHCARE	10MG/ML	N75799 001	APR 30, 2002		APR	NEWA
	FAMOTIDINE PRESERVATIVE FREE							
	@	APOTHECON	10MG/ML	N75708 001	APR 16, 2001		MAR	WDAG
AP		BAXTER HLTHCARE	10MG/ML	N75789 001	APR 30, 2002		APR	NEWA

FENOFIBRATE
CAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

	AB		TEVA	134MG	N75753 002	APR 09, 2002	APR	NEWA
	AB			200MG	N75753 003	APR 09, 2002	APR	NEWA

TRICOR (MICRONIZED)

	AB		ABBOTT	134MG	N19304 003	JUN 30, 1999	APR	CFTG
	AB	+		200MG	N19304 004	JUN 30, 1999	APR	CFTG

FENOPROFEN CALCIUM
CAPSULE; ORAL
NALFON

>D>	AB	+	DISTA	EQ 300MG BASE	N17604 002		JUN	CAHN
>A>	AB	+	RANBAXY	EQ 300MG BASE	N17604 002		JUN	CAHN

NALFON 200

>D>	AB		DISTA	EQ 200MG BASE	N17604 003		JUN	CAHN
>A>	AB		RANBAXY	EQ 200MG BASE	N17604 003		JUN	CAHN

FENTANYL CITRATE
TROCHE/LOZENGE; ORAL
FENTANYL

>D>			ANESTA	EQ 0.1MG BASE	N20195 007	OCT 30, 1995	JUN	DISC
>A>			@	EQ 0.1MG BASE	N20195 007	OCT 30, 1995	JUN	DISC
>D>				EQ 0.2MG BASE	N20195 001	OCT 04, 1993	JUN	DISC
>A>			@	EQ 0.2MG BASE	N20195 001	OCT 04, 1993	JUN	DISC
>D>				EQ 0.3MG BASE	N20195 002	OCT 04, 1993	JUN	DISC
>A>			@	EQ 0.3MG BASE	N20195 002	OCT 04, 1993	JUN	DISC
>D>		+		EQ 0.4MG BASE	N20195 003	OCT 04, 1993	JUN	DISC
>A>			@	EQ 0.4MG BASE	N20195 003	OCT 04, 1993	JUN	DISC

FLOXURIDINE
INJECTABLE; INJECTION
FUDR

	AP	+	FAULDING	500MG/VIAL	N16929 001		APR	CAHN

FLUDROCORTISONE ACETATE
TABLET; ORAL
FLORINEF

	AB	+	KING PHARMS	0.1MG	N10060 001		MAR	CFTG

FLUDROCORTISONE ACETATE

	AB		IMPAX LABS	0.1MG	N40431 001	MAR 18, 2002	MAR	NEWA

FLUNISOLIDE
SPRAY, METERED; NASAL
FLUNISOLIDE

	AB		BAUSCH AND LOMB	0.025MG/SPRAY	N74805 001	FEB 20, 2002	FEB	NEWA

NASALIDE

	AB	+	IVAX RES	0.025MG/SPRAY	N18148 001		FEB	CTEC

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

>D>	SYNALAR-HP						
>D>	+ MEDICIS	0.2%	N16161 002		JUN	DISC	
>A>	@	0.2%	N16161 002		JUN	DISC	

SOLUTION; TOPICAL

FLUONID						
@ ALLERGAN HERBERT	0.01%	N87158 001	MAR 17, 1983	MAY	DISC	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA						
+ HILL DERMAC	0.01%;4%;0.05%	N21112 001	JAN 18, 2002	JAN	NEWA	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE						
AB ALPHAPHARM	EQ 10MG BASE	N75577 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75577 002	JAN 29, 2002	JAN	NEWA	
AB BARR	EQ 10MG BASE	N74803 002	JAN 30, 2002	JAN	NEWA	
AB CARLSBAD	EQ 10MG BASE	N76022 001	JAN 30, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N76022 002	JAN 30, 2002	JAN	NEWA	
AB DR REDDYS LABS INC	EQ 10MG BASE	N75465 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75465 002	JAN 29, 2002	JAN	NEWA	
AB EON	EQ 10MG BASE	N75807 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75807 002	JAN 29, 2002	JAN	NEWA	
AB IVAX PHARMS	EQ 10MG BASE	N75245 002	JAN 31, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75245 001	JAN 31, 2002	JAN	NEWA	
AB MALLINCKRODT	EQ 10MG BASE	N75658 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75658 002	JAN 29, 2002	JAN	NEWA	
AB MUTUAL PHARMA	EQ 10MG BASE	N75787 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75787 002	JAN 29, 2002	JAN	NEWA	
AB MYLAN	EQ 10MG BASE	N75207 001	JAN 30, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75207 002	JAN 30, 2002	JAN	NEWA	
AB RANBAXY	EQ 10MG BASE	N76165 001	FEB 01, 2002	FEB	NEWA	
AB	EQ 20MG BASE	N76165 002	FEB 01, 2002	FEB	NEWA	
AB SIDMAK LABS	EQ 10MG BASE	N76001 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N76001 002	JAN 29, 2002	JAN	NEWA	
AB SIEGFRIED	EQ 10MG BASE	N75464 001	JAN 30, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75464 002	JAN 30, 2002	JAN	NEWA	
AB TEVA	EQ 10MG BASE	N75452 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75452 002	JAN 29, 2002	JAN	NEWA	
AB	EQ 40MG BASE	N75452 003	JAN 29, 2002	JAN	NEWA	
AB WATSON LABS	EQ 10MG BASE	N75662 001	JAN 29, 2002	JAN	NEWA	
AB	EQ 20MG BASE	N75662 002	JAN 29, 2002	JAN	NEWA	
FLUOXETINE HCL						
AB GENEVA PHARMS	EQ 20MG BASE	N75049 002	JAN 29, 2002	JAN	NEWA	
AB	EQ 40MG BASE	N75049 003	JAN 29, 2002	JAN	NEWA	

SOLUTION; ORAL

FLUOXETINE						
AA ALPHARMA	EQ 20MG BASE/5ML	N75690 001	JAN 31, 2002	JAN	NEWA	
AA MALLINCKRODT	EQ 20MG BASE/5ML	N75920 001	JAN 29, 2002	JAN	NEWA	

	AA	NOVEX	EQ 20MG BASE/5ML	N75292 001	FEB 07, 2002	FEB	NEWA
	AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015 001	JAN 30, 2002	JAN	NEWA
		FLUOXETINE HCL					
>A>	AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525 001	JUN 27, 2002	JUN	NEWA
		TABLET; ORAL					
	AB	BARR	EQ 10MG BASE	N75810 001	FEB 01, 2002	FEB	NEWA
	AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001	JAN 30, 2002	JAN	NEWA
	AB	EON	EQ 10MG BASE	N76024 001	JAN 29, 2002	JAN	NEWA
	AB	TEVA	EQ 10MG BASE	N75872 001	JAN 29, 2002	JAN	NEWA
	AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001	FEB 28, 2002	FEB	NEWA
		FLUPHENAZINE ENANTHATE					
>D>		INJECTABLE; INJECTION					
>D>		PROLIXIN ENANTHATE					
>D>	+	APOTHECON	25MG/ML	N16110 001		JUN	DISC
>A>		@	25MG/ML	N16110 001		JUN	DISC
		FLUVOXAMINE MALEATE					
		TABLET; ORAL					
		FLUVOXAMINE MALEATE					
	AB +	EON	100MG	N75888 003	NOV 29, 2000	MAY	CRLD
	AB	MUTUAL PHARM	25MG	N76125 001	APR 29, 2002	APR	NEWA
	AB		50MG	N76125 002	APR 29, 2002	APR	NEWA
	AB		100MG	N76125 003	APR 29, 2002	APR	NEWA
		LUVOX					
		@ SOLVAY	25MG	N20243 001	DEC 05, 1994	MAY	DISC
		@	50MG	N20243 002	DEC 05, 1994	MAY	DISC
		@	100MG	N20243 003	DEC 05, 1994	MAY	DISC
		FOLIC ACID					
		TABLET; ORAL					
		FOLIC ACID					
	AA +	WATSON LABS	1MG	N80680 001		FEB	CAHN
		FOLLITROPIN ALFA/BETA					
>D>		INJECTABLE; INJECTION					
>D>		GONAL-F					
>D>		SERONO	37.5 IU/VIAL	N20378 003	MAY 25, 2000	JUN	DISC
>A>		@	37.5 IU/VIAL	N20378 003	MAY 25, 2000	JUN	DISC
		FULVESTRANT					
		INJECTABLE; INTRAMUSCULAR					
		FASLODEX					
	+	ASTRAZENECA	50MG/ML	N21344 001	APR 25, 2002	APR	NEWA
		GALLIUM CITRATE, GA-67					
		INJECTABLE; INJECTION					
>D>		NEOSCAN					
>D>	BS	AMERSHAM HLTH	2mCi/ML	N17655 001		JUN	DISC
>A>		@	2mCi/ML	N17655 001		JUN	DISC

GLATIRAMER ACETATE

>D>	INJECTABLE; INJECTION						
>D>	COPAXONE						
>D>	+ TEVA	20MG/VIAL	N20622 001	DEC 20, 1996	JUN	CDFR	
>A>	FOR SOLUTION; SUBCUTANEOUS						
>A>	COPAXONE						
>A>	+ TEVA	20MG/VIAL	N20622 001	DEC 20, 1996	JUN	CDFR	
>A>	INJECTABLE; SUBCUTANEOUS						
>A>	+ TEVA	20MG/ML	N20622 002	FEB 12, 2002	JUN	NEWA	

GLIPIZIDE

	TABLET, EXTENDED RELEASE; ORAL						
	GLUCOTROL XL						
	PFIZER	2.5MG	N20329 003	AUG 10, 1999	FEB	CRLD	
		5MG	N20329 001	APR 26, 1994	FEB	CRLD	

GLUCAGON HYDROCHLORIDE

>D>	INJECTABLE; INJECTION						
>D>	GLUCAGON						
>D>	+ LILLY	EQ 1MG BASE/VIAL	N12122 001		JUN	DISC	
>A>	@	EQ 1MG BASE/VIAL	N12122 001		JUN	DISC	

GLYBURIDE

	TABLET; ORAL						
	GLYBURIDE						
>A> AB	COREPHARMA	1.25MG	N76257 001	JUN 27, 2002	JUN	NEWA	
>A> AB		2.5MG	N76257 002	JUN 27, 2002	JUN	NEWA	
>A> AB		5MG	N76257 003	JUN 27, 2002	JUN	NEWA	

GONADORELIN ACETATE

>D>	INJECTABLE; INJECTION						
>D>	LUTREPULSE KIT						
>D>	+ FERRING	3.2MG/VIAL	N19687 002	OCT 10, 1989	JUN	DISC	
>A>	@	3.2MG/VIAL	N19687 002	OCT 10, 1989	JUN	DISC	

GONADORELIN HYDROCHLORIDE

>D>	INJECTABLE; INJECTION						
>D>	FACTREL						
>D>	+ WYETH AYERST	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	JUN	DISC	
>A>	@	EQ 0.5MG BASE/VIAL	N18123 003	SEP 30, 1982	JUN	DISC	

GONADOTROPIN, CHORIONIC

	INJECTABLE; INJECTION						
	A.P.L.						
>D>	+ WYETH AYERST	20,000 UNITS/VIAL	N17055 003		JUN	DISC	
>A>	@	20,000 UNITS/VIAL	N17055 003		JUN	DISC	
	CHORIONIC GONADOTROPIN						
>D>	+ STERIS	2,000 UNITS/VIAL	N17016 011	FEB 16, 1990	JUN	DISC	
>A>	@	2,000 UNITS/VIAL	N17016 011	FEB 16, 1990	JUN	DISC	

GRANISETRON HYDROCHLORIDE

>D>	SOLUTION; ORAL						
>D>	KYTRIL						
>D>	+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	DISC	

>A>	@	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	DISC

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

GRISACTIN

@ WYETH AYERST	500MG	N60212 001			MAY	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRISACTIN ULTRA

@ WYETH AYERST	165MG	N62438 001	NOV 17, 1983	MAY	DISC
@	330MG	N62438 002	NOV 17, 1983	MAY	DISC

GUANADREL SULFATE

TABLET; ORAL

HYLOREL

>D>	PHARMACIA AND UPJOHN	10MG	N18104 001	DEC 29, 1982	JUN	DISC
>D>	@	10MG	N18104 001	DEC 29, 1982	JUN	DISC
>A>	+	25MG	N18104 002	DEC 29, 1982	JUN	DISC
>D>	@	25MG	N18104 002	DEC 29, 1982	JUN	DISC
>A>						

GUANETHIDINE MONOSULFATE

TABLET; ORAL

ISMELIN

>D>	NOVARTIS	EQ 10MG SULFATE	N12329 001		JUN	DISC
>D>	@	EQ 10MG SULFATE	N12329 001		JUN	DISC
>A>	+	EQ 25MG SULFATE	N12329 002		JUN	DISC
>D>	@	EQ 25MG SULFATE	N12329 002		JUN	DISC
>A>						

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

TENEX

AB	ESP PHARMA	EQ 1MG BASE	N19032 001	OCT 27, 1986	APR	CAHN
AB	+	EQ 2MG BASE	N19032 002	NOV 07, 1988	APR	CAHN
	@	EQ 3MG BASE	N19032 003	NOV 07, 1988	APR	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

@ ALPHARMA	EQ 2MG BASE/ML	N70318 001	APR 11, 1986	MAY	DISC

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

@ WYETH AYERST	99.99%	N11338 001			APR	DISC

HALOTHANE

AN	+ ABBOTT	99.99%	N83254 001			APR	CTEC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP-LOCK

>D>	AP ELKINS SINN	10 UNITS/ML	N17037 007			JUN	CRLD
>A>	AP +	10 UNITS/ML	N17037 007			JUN	CRLD

>D>	AP		100 UNITS/ML	N17037 006		JUN	CRLD
>A>	AP +		100 UNITS/ML	N17037 006		JUN	CRLD
		HEPARIN LOCK FLUSH					
>D>	AP +	WYETH AYERST	10 UNITS/ML	N17007 008		JUN	DISC
>A>		@	10 UNITS/ML	N17007 008		JUN	DISC
>D>	AP +		100 UNITS/ML	N17007 009		JUN	DISC
>A>		@	100 UNITS/ML	N17007 009		JUN	DISC
		HEPARIN SODIUM					
>D>	AP	ABBOTT	2,500 UNITS/ML	N88099 001	APR 28, 1983	JUN	CRLD
>A>	AP +		2,500 UNITS/ML	N88099 001	APR 28, 1983	JUN	CRLD
>D>	AP	AM PHARM PARTNERS	20,000 UNITS/ML	N17029 004		JUN	CRLD
>A>	AP +		20,000 UNITS/ML	N17029 004		JUN	CRLD
>D>	AP	WYETH AYERST	1,000 UNITS/ML	N17007 001		JUN	DISC
>A>		@	1,000 UNITS/ML	N17007 001		JUN	DISC
>D>	AP +		2,500 UNITS/ML	N17007 007		JUN	DISC
>A>		@	2,500 UNITS/ML	N17007 007		JUN	DISC
>D>	AP		5,000 UNITS/ML	N17007 002		JUN	DISC
>D>	AP		5,000 UNITS/0.5ML	N17007 010		JUN	DISC
>A>		@	5,000 UNITS/ML	N17007 002		JUN	DISC
>A>		@	5,000 UNITS/0.5ML	N17007 010		JUN	DISC
>D>	+		7,500 UNITS/ML	N17007 003		JUN	DISC
>A>		@	7,500 UNITS/ML	N17007 003		JUN	DISC
>D>	AP		10,000 UNITS/ML	N17007 004		JUN	DISC
>A>		@	10,000 UNITS/ML	N17007 004		JUN	DISC
>D>	AP +		20,000 UNITS/ML	N17007 006		JUN	DISC
>A>		@	20,000 UNITS/ML	N17007 006		JUN	DISC
	HEXACHLOROPHENE						
>D>	SOAP; TOPICAL						
>D>	GAMOPHEN						
>D>	+	ARBROOK	2%	N06270 003		JUN	DISC
>A>		@	2%	N06270 003		JUN	DISC
>D>	SPONGE; TOPICAL						
>D>	E-Z SCRUB						
>D>	+	BECTON DICKINSON	450MG	N17452 001		JUN	DISC
>A>		@	450MG	N17452 001		JUN	DISC
	HYDROCHLOROTHIAZIDE						
	TABLET; ORAL						
	ESIDRIX						
	AB +	NOVARTIS	100MG	N11793 009		MAR	CRLD
		HYDROCHLOROTHIAZIDE					
	AB	VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002	MAR	NEWA
	AB		50MG	N40412 002	MAR 29, 2002	MAR	NEWA
		HYDRODIURIL					
		@ MERCK	25MG	N11835 003		MAR	DISC
		@	50MG	N11835 006		MAR	DISC
		@	100MG	N11835 007		MAR	DISC
	HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE						
	TABLET; ORAL						
	UNIRETIC						
>A>		SCHWARZ PHARMA	12.5MG;15MG	N20729 003	FEB 14, 2002	JUN	NEWA

		HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE						
>D>		CAPSULE, EXTENDED RELEASE; ORAL						
>D>		INDERIDE LA 120/50						
>D>		+ WYETH AYERST	50MG;120MG	N19059 002	JUL 03, 1985	JUN	DISC	
>A>		@	50MG;120MG	N19059 002	JUL 03, 1985	JUN	DISC	
>D>		INDERIDE LA 160/50						
>D>		+ WYETH AYERST	50MG;160MG	N19059 003	JUL 03, 1985	JUN	DISC	
>A>		@	50MG;160MG	N19059 003	JUL 03, 1985	JUN	DISC	
>D>		INDERIDE LA 80/50						
>D>		+ WYETH AYERST	50MG;80MG	N19059 001	JUL 03, 1985	JUN	DISC	
>A>		@	50MG;80MG	N19059 001	JUL 03, 1985	JUN	DISC	
		HYDROCHLOROTHIAZIDE; RESERPINE						
>D>		TABLET; ORAL						
>D>		HYDROPRES 25						
>D>	BP	MERCK	25MG;0.125MG	N11958 002		JUN	DISC	
>A>		@	25MG;0.125MG	N11958 002		JUN	DISC	
>D>		HYDROPRES 50						
>D>	BP	+ MERCK	50MG;0.125MG	N11958 003		JUN	DISC	
>A>		@	50MG;0.125MG	N11958 003		JUN	DISC	
		HYDROCORTISONE						
		TABLET; ORAL						
		CORTEF						
		+ PHARMACIA AND UPJOHN	5MG	N08697 003		MAY	CRLD	
	BP	+	10MG	N08697 001		MAY	CRLD	
	BP	+	20MG	N08697 002		MAY	CRLD	
		HYDROCORTISONE ACETATE						
		CREAM; TOPICAL						
		MICORT-HC						
		+ FERNDALE LABS	2%	N40398 001	MAR 29, 2002	MAR	NEWA	
		INJECTABLE; INJECTION						
		HYDROCORTISONE ACETATE						
>D>	BP	STERIS	25MG/ML	N83128 001		JUN	CRLD	
>A>		+	25MG/ML	N83128 001		JUN	CRLD	
>D>		HYDROCORTONE						
>D>	BP	MERCK	25MG/ML	N08228 001		JUN	DISC	
>A>		@	25MG/ML	N08228 001		JUN	DISC	
>D>		+	50MG/ML	N08228 004		JUN	DISC	
>A>		@	50MG/ML	N08228 004		JUN	DISC	
		HYDROCORTISONE BUTYRATE						
		CREAM; TOPICAL						
		LOCOID						
		+ FERNDALE LABS	0.1%	N18514 001	MAR 31, 1982	MAR	CAHN	
		LOCOID LIPOCREAM						
		+ FERNDALE LABS	0.1%	N20769 001	SEP 08, 1997	MAR	CAHN	
		OINTMENT; TOPICAL						
		LOCOID						
		+ FERNDALE LABS	0.1%	N18652 001	OCT 29, 1982	MAR	CAHN	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE
>D> OINTMENT; OPHTHALMIC
>D> ACHROMYCIN
>D> + LEDERLE 1.5%;1% N50272 001 JUN DISC
>A> @ 1.5%;1% N50272 001 JUN DISC

HYDROXYAMPHETAMINE HYDROBROMIDE
>D> SOLUTION/DROPS; OPHTHALMIC
>D> PAREDRINE
>D> + AKORN 1% N00004 004 JUN DISC
>A> @ 1% N00004 004 JUN DISC

HYDROXYPROGESTERONE CAPROATE
>D> INJECTABLE; INJECTION
>D> HYDROXYPROGESTERONE CAPROATE
>D> + STERIS 250MG/ML N17439 002 JUN DISC
>A> @ 250MG/ML N17439 002 JUN DISC

HYDROXYZINE HYDROCHLORIDE
SYRUP; ORAL
HYDROXYZINE HCL
AA VINTAGE PHARMS 10MG/5ML N40391 001 APR 10, 2002 APR NEWA

IBUPROFEN
>D> SUSPENSION/DROPS; ORAL
>D> MOTRIN
>D> + MCNEIL 40MG/ML N20476 001 MAY 25, 1995 JUN DISC
>A> @ 40MG/ML N20476 001 MAY 25, 1995 JUN DISC
TABLET; ORAL
>D> MCNEIL CONS SPECLT 100MG N20418 001 NOV 16, 1994 JUN DISC
>A> @ 100MG N20418 001 NOV 16, 1994 JUN DISC
TABLET, CHEWABLE; ORAL
>D> MCNEIL CONS SPECLT 50MG N20135 001 NOV 16, 1994 JUN DISC
>A> @ 50MG N20135 001 NOV 16, 1994 JUN DISC
>D> + 100MG N20135 002 NOV 16, 1994 JUN DISC
>A> @ 100MG N20135 002 NOV 16, 1994 JUN DISC

IDARUBICIN HYDROCHLORIDE
INJECTABLE; INJECTION
>D> IDAMYCIN
>D> AP + PHARMACIA AND UPJOHN 5MG/VIAL N50661 002 SEP 27, 1990 JUN DISC
>A> @ 5MG/VIAL N50661 002 SEP 27, 1990 JUN DISC
AP + 5MG/VIAL N50661 002 SEP 27, 1990 MAY CFTG
>D> AP + 10MG/VIAL N50661 001 SEP 27, 1990 JUN DISC
>A> @ 10MG/VIAL N50661 001 SEP 27, 1990 JUN DISC
AP + 10MG/VIAL N50661 001 SEP 27, 1990 MAY CFTG
>D> AP + 20MG/VIAL N50661 003 APR 25, 1995 JUN DISC
>A> @ 20MG/VIAL N50661 003 APR 25, 1995 JUN DISC
AP + 20MG/VIAL N50661 003 APR 25, 1995 MAY CFTG
IDAMYCIN PFS
AP + PHARMACIA AND UPJOHN 1MG/ML N50734 001 FEB 17, 1997 MAY CFTG
IDARUBICIN HCL

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HCL

	AP		GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002	MAY	NEWA
>D>	AP			10MG/VIAL	N65037 002	MAY 01, 2002	JUN	CRLD
>A>		+		10MG/VIAL	N65037 002	MAY 01, 2002	JUN	CRLD
	AP			10MG/VIAL	N65037 002	MAY 01, 2002	MAY	NEWA
>D>	AP			20MG/VIAL	N65037 001	MAY 01, 2002	JUN	CRLD
>A>		+		20MG/VIAL	N65037 001	MAY 01, 2002	JUN	CRLD
	AP			20MG/VIAL	N65037 001	MAY 01, 2002	MAY	NEWA

IDARUBICIN HCL PFS

	AP		GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002	MAY	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFSOFAMIDE

			AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002	MAY	NEWA
		+		3GM/VIAL	N76078 002	MAY 28, 2002	MAY	NEWA

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

		+	GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 001	FEB 26, 2002	FEB	NEWA
		+		3GM /60ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 002	FEB 26, 2002	FEB	NEWA

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

>D>	AP		ABBOTT	EQ 5MG BASE/ML	N74616 001	AUG 03, 1998	JUN	CRLD
>A>	AP	+		EQ 5MG BASE/ML	N74616 001	AUG 03, 1998	JUN	CRLD

>D> INOCOR

>D>	AP	+	SANOFI SYNTHELABO	EQ 5MG BASE/ML	N18700 001	JUL 31, 1984	JUN	DISC
>A>		@		EQ 5MG BASE/ML	N18700 001	JUL 31, 1984	JUN	DISC

INDOCYANINE GREEN

INJECTABLE; INJECTION

CARDIO-GREEN

>D>		+	AKORN	50MG/VIAL	N11525 002		JUN	DISC
>A>		@		50MG/VIAL	N11525 002		JUN	DISC

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

	AB		ABLE	75MG	N76114 001	FEB 06, 2002	FEB	NEWA

SUPPOSITORY; RECTAL

INDOCIN

		@	MERCK	50MG	N17814 001	AUG 13, 1984	MAY	DISC

INDOMETHEGAN

		+	G AND W LABS	50MG	N73314 001	AUG 31, 1992	MAY	CRLD

	INSULIN PORK						
>D>	INJECTABLE; INJECTION						
>D>	ILETIN I						
>D>	+ LILLY	500 UNITS/ML	N17931 001		JUN	DISC	
	INSULIN RECOMBINANT HUMAN						
>D>	INJECTABLE; INJECTION						
>D>	VELOSULIN BR						
>D>	+ NOVO NORDISK	100 UNITS/ML	N21028 001	JUL 19, 1999	JUN	CMS2	
	IODIPAMIDE MEGLUMINE						
	INJECTABLE; INJECTION						
	CHOLOGRAFIN MEGLUMINE						
>D>	+ BRACCO	10.3%	N09321 007		JUN	DISC	
>A>	@	10.3%	N09321 007		JUN	DISC	
	IODIXANOL						
	INJECTABLE; INJECTION						
	VISIPAQUE 270						
>D>	AMERSHAM HLTH	55%	N20808 001	AUG 29, 1997	JUN	DISC	
>A>	@	55%	N20808 001	AUG 29, 1997	JUN	DISC	
	VISIPAQUE 320						
>D>	AMERSHAM HLTH	65.2%	N20808 002	AUG 29, 1997	JUN	DISC	
>A>	@	65.2%	N20808 002	AUG 29, 1997	JUN	DISC	
	IODOHIPPURATE SODIUM, I-131						
>D>	INJECTABLE; INJECTION						
>D>	HIPPURAN I 131						
>D>	MALLINCKRODT	0.25mCi/ML	N16666 001		JUN	DISC	
>A>	@	0.25mCi/ML	N16666 001		JUN	DISC	
	IOFETAMINE HYDROCHLORIDE I-123						
>D>	INJECTABLE; INJECTION						
>D>	SPECTAMINE						
>D>	IMP	1mCi/ML	N19432 001	DEC 24, 1987	JUN	DISC	
>A>	@	1mCi/ML	N19432 001	DEC 24, 1987	JUN	DISC	
	IOHEXOL						
	INJECTABLE; INJECTION						
>D>	OMNIPAQUE 210						
>D>	+ AMERSHAM HLTH	45.3%	N18956 006	JUN 30, 1989	JUN	DISC	
>A>	@	45.3%	N18956 006	JUN 30, 1989	JUN	DISC	
>D>	SOLUTION; URETHRAL						
>D>	OMNIPAQUE 70						
>D>	+ AMERSHAM HLTH	15.1%	N18956 007	JUN 01, 1994	JUN	DISC	
>A>	@	15.1%	N18956 007	JUN 01, 1994	JUN	DISC	
	IOPAMIDOL						
	INJECTABLE; INJECTION						
>D>	ISOVUE-128						
>D>	+ BRACCO	26%	N18735 005	OCT 21, 1986	JUN	DISC	
>A>	@	26%	N18735 005	OCT 21, 1986	JUN	DISC	

IOTHALAMATE SODIUM
INJECTABLE; INJECTION
>D> CONRAY 325
>D> + MALLINCKRODT 54.3% N17685 001 JUN DISC
>A> @ 54.3% N17685 001 JUN DISC

IOXILAN
INJECTABLE; INJECTION
OXILAN-300
>D> COOK IMAGING 62% N20316 001 DEC 21, 1995 JUN CAHN
>A> GUERBET 62% N20316 001 DEC 21, 1995 JUN CAHN
OXILAN-350
>D> COOK IMAGING 73% N20316 002 DEC 21, 1995 JUN CAHN
>A> GUERBET 73% N20316 002 DEC 21, 1995 JUN CAHN

IPODATE SODIUM
CAPSULE; ORAL
>D> ORAGRAFIN SODIUM
>D> + BRACCO 500MG N12967 001 JUN DISC
>A> @ 500MG N12967 001 JUN DISC

ISOPROTERENOL HYDROCHLORIDE
>D> AEROSOL, METERED; INHALATION
>D> ISOPROTERENOL HCL
>D> + 3M 0.12MG/INH N10375 004 JUN DISC
>A> + @ 0.12MG/INH N10375 004 JUN DISC

ISOPROTERENOL SULFATE
>D> AEROSOL, METERED; INHALATION
>D> MEDIHALER-ISO
>D> + 3M 0.08MG/INH N10375 003 JUN DISC
>A> @ 0.08MG/INH N10375 003 JUN DISC

ISOSORBIDE
>D> SOLUTION; ORAL
>D> ISMOTIC
>D> ALCON 100GM/220ML N17063 001 JUN DISC
>A> @ 100GM/220ML N17063 001 JUN DISC

KETOCONAZOLE
TABLET; ORAL
KETOCONAZOLE
AB TORPHARM 200MG N75912 001 JAN 10, 2002 JAN NEWA

KETOPROFEN
CAPSULE, EXTENDED RELEASE; ORAL
KETOPROFEN
AB MYLAN 100MG N75679 003 FEB 20, 2002 FEB NEWA
AB 150MG N75679 002 FEB 20, 2002 FEB NEWA
AB 200MG N75679 001 FEB 20, 2002 FEB NEWA

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	AM PHARM PARTNERS	15MG/ML	N75784 001	JAN 11, 2002	JAN	NEWA
AP		30MG/ML	N75784 002	JAN 11, 2002	JAN	NEWA

LACTULOSE
SOLUTION; ORAL
LACTULOSE

AA	NOVEX	10GM/15ML	N75911 001	FEB 21, 2002	FEB	NEWA

LAMOTRIGINE
TABLET, CHEWABLE; ORAL
LAMICTAL CD

+	GLAXOSMITHKLINE	25MG	N20764 002	AUG 24, 1998	MAR	CRLD
	@	100MG	N20764 003	AUG 24, 1998	MAR	DISC

LEUCOVORIN CALCIUM
TABLET; ORAL
LEUCOVORIN CALCIUM

>D>	AB	IMMUNEX	EQ 15MG BASE	N71104 001	MAR 04, 1987	JUN	CAHN
>A>	AB	XANODYNE PHARM	EQ 15MG BASE	N71104 001	MAR 04, 1987	JUN	CAHN

LEUPROLIDE ACETATE
INJECTABLE; SUBCUTANEOUS
ELIGARD

+	ATRIX	7.5MG/VIAL	N21343 001	JAN 23, 2002	JAN	NEWA

LEVALBUTEROL HYDROCHLORIDE
SOLUTION; INHALATION
XOPENEX

>A>	+	SEPRACOR	EQ 0.0105% BASE	N20837 003	JAN 30, 2002	JUN	NEWA

LEVOCARNITINE
SOLUTION; ORAL
CARNITOR

>D>	+	SIGMA TAU	1GM/10ML	N18948 002	APR 27, 1988	JUN	DISC
>A>	@		1GM/10ML	N18948 002	APR 27, 1988	JUN	DISC
>D>	+		1GM/10ML	N19257 001	APR 10, 1986	JUN	DISC
>A>	@		1GM/10ML	N19257 001	APR 10, 1986	JUN	DISC

LEVODOPA
TABLET; ORAL
LARODOPA

>D>		ROCHE	100MG	N16912 005		JUN	DISC
>A>	@		100MG	N16912 005		JUN	DISC
>D>			250MG	N16912 003		JUN	DISC
>A>	@		250MG	N16912 003		JUN	DISC
>D>	+		500MG	N16912 004		JUN	DISC
>A>	@		500MG	N16912 004		JUN	DISC

LEVOTHYROXINE SODIUM

TABLET; ORAL

>A>		LEVO-T						
	BX	MOVA	0.025MG	N21342 001	MAR 01, 2002	MAR	NEWA	
	BX		0.05MG	N21342 002	MAR 01, 2002	MAR	NEWA	
	BX		0.075MG	N21342 003	MAR 01, 2002	MAR	NEWA	
	BX		0.088MG	N21342 004	MAR 01, 2002	MAR	NEWA	
	BX		0.1MG	N21342 005	MAR 01, 2002	MAR	NEWA	
	BX		0.112MG	N21342 006	MAR 01, 2002	MAR	NEWA	
	BX		0.125MG	N21342 007	MAR 01, 2002	MAR	NEWA	
	BX		0.15MG	N21342 008	MAR 01, 2002	MAR	NEWA	
	BX		0.175MG	N21342 009	MAR 01, 2002	MAR	NEWA	
	BX		0.2MG	N21342 010	MAR 01, 2002	MAR	NEWA	
	BX +		0.3MG	N21342 011	MAR 01, 2002	MAR	NEWA	
>A>		LEVOTHYROXINE SODIUM						
>A>	AB	MYLAN	0.025MG	N76187 001	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.05MG	N76187 002	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.075MG	N76187 003	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.088MG	N76187 004	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.1MG	N76187 005	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.112MG	N76187 006	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.125MG	N76187 007	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.15MG	N76187 008	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.175MG	N76187 009	JUN 05, 2002	JUN	NEWA	
>A>	AB		0.2MG	N76187 010	JUN 05, 2002	JUN	NEWA	
>A>	AB +		0.3MG	N76187 011	JUN 05, 2002	JUN	NEWA	
>A>		NOVOTHYROX						
	BX	GENPHARM	0.025MG	N21292 001	MAY 31, 2002	MAY	NEWA	
	BX		0.05MG	N21292 002	MAY 31, 2002	MAY	NEWA	
	BX		0.075MG	N21292 003	MAY 31, 2002	MAY	NEWA	
	BX		0.088MG	N21292 004	MAY 31, 2002	MAY	NEWA	
	BX		0.1MG	N21292 005	MAY 31, 2002	MAY	NEWA	
	BX		0.112MG	N21292 006	MAY 31, 2002	MAY	NEWA	
	BX		0.125MG	N21292 007	MAY 31, 2002	MAY	NEWA	
	BX		0.137MG	N21292 008	MAY 31, 2002	MAY	NEWA	
	BX		0.15MG	N21292 009	MAY 31, 2002	MAY	NEWA	
	BX		0.175MG	N21292 010	MAY 31, 2002	MAY	NEWA	
	BX		0.2MG	N21292 011	MAY 31, 2002	MAY	NEWA	
	BX +		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA	
>A>		UNITHROID						
>D>	BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD	
>A>	AB		0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD	
>D>	BX		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD	
>A>	AB		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD	
>D>	BX		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD	
>A>	AB		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD	
>D>	BX		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD	
>A>	AB		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD	
>D>	BX		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD	
>A>	AB		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD	
>D>	BX		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD	
>A>	AB		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD	

>D>	BX		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD
>A>	AB		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD
>D>	BX		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD
>A>	AB		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD
>D>	BX		0.175MG	N21210 009	AUG 21, 2000	JUN	CRLD
>A>	AB		0.175MG	N21210 009	AUG 21, 2000	JUN	CRLD
>D>	BX		0.2MG	N21210 010	AUG 21, 2000	JUN	CRLD
>A>	AB		0.2MG	N21210 010	AUG 21, 2000	JUN	CRLD
>D>	BX	+	0.3MG	N21210 011	AUG 21, 2000	JUN	CRLD
>A>	AB	+	0.3MG	N21210 011	AUG 21, 2000	JUN	CRLD

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

>D>		+	ASTRAZENECA	10%	N14394 001		JUN	DISC
>A>		@		10%	N14394 001		JUN	DISC

FILM, EXTENDED RELEASE; BUCCAL

LIDOCAINE

>D>		+	NOVEN	46.1MG/PATCH	N20575 002	MAY 21, 1996	JUN	DISC
>A>		@		46.1MG/PATCH	N20575 002	MAY 21, 1996	JUN	DISC

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

>D>			PHARMACIA AND UPJOHN	EQ 250MG BASE	N50316 001		JUN	DISC
>A>		@		EQ 250MG BASE	N50316 001		JUN	DISC
>D>		+		EQ 500MG BASE	N50316 002		JUN	DISC
>A>		@		EQ 500MG BASE	N50316 002		JUN	DISC

LINEZOLID

TABLET; ORAL

ZYVOX

>D>			PHARMACIA AND UPJOHN	400MG	N21130 001	APR 18, 2000	JUN	DISC
>A>		@		400MG	N21130 001	APR 18, 2000	JUN	DISC

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

>A>	AB		WEST WARD	300MG	N76243 001	JUN 27, 2002	JUN	NEWA

TABLET, EXTENDED RELEASE; ORAL

>A>	AB		BARR	300MG	N76170 001	JUN 10, 2002	JUN	NEWA

LITHOBID

>D>		+	SOLVAY	300MG	N18027 001		JUN	CFTG
>A>	AB	+		300MG	N18027 001		JUN	CFTG

LOVASTATIN

TABLET; ORAL

LOVASTATIN

>A>	AB		CARLSBAD	10MG	N75991 001	JUN 05, 2002	JUN	NEWA
>A>	AB			20MG	N75991 002	JUN 05, 2002	JUN	NEWA
>A>	AB			40MG	N75991 003	JUN 05, 2002	JUN	NEWA

TABLET, EXTENDED RELEASE; ORAL

ALTOCOR

		LOVASTATIN						
>A>		TABLET, EXTENDED RELEASE; ORAL						
>A>		ALTOCOR						
>A>		AURA LABS	10MG	N21316 001	JUN 26, 2002	JUN	NEWA	
>A>			20MG	N21316 002	JUN 26, 2002	JUN	NEWA	
>A>			40MG	N21316 003	JUN 26, 2002	JUN	NEWA	
>A>	+		60MG	N21316 004	JUN 26, 2002	JUN	NEWA	
		MANGANESE CHLORIDE TETRAHYDRATE						
>D>		FOR SOLUTION; ORAL						
>D>		LUMENHANCE						
>D>	+	BRACCO	3.49MG/GM	N20686 001	DEC 19, 1997	JUN	DISC	
>A>		@	3.49MG/GM	N20686 001	DEC 19, 1997	JUN	DISC	
		MASOPROCOL						
>D>		CREAM; TOPICAL						
>D>		ACTINEX						
>D>	+	UNIV AZ CANCER CTR	10%	N19940 001	SEP 04, 1992	JUN	DISC	
>A>		@	10%	N19940 001	SEP 04, 1992	JUN	DISC	
		MAZINDOL						
		TABLET; ORAL						
		MAZANOR						
		@ WYETH AYERST	1MG	N17980 002		APR	DISC	
>D>		SANOREX						
>D>		NOVARTIS	1MG	N17247 001		JUN	DISC	
>A>		@	1MG	N17247 001		JUN	DISC	
			1MG	N17247 001		APR	CTEC	
>D>	+		2MG	N17247 002		JUN	DISC	
>A>		@	2MG	N17247 002		JUN	DISC	
		MEFLOQUINE HYDROCHLORIDE						
		TABLET; ORAL						
		LARIAM						
	AB +	ROCHE	250MG	N19591 001	MAY 02, 1989	FEB	CFTG	
		MEFLOQUINE HCL						
	AB	GENEVA PHARMS TECH	250MG	N76175 001	FEB 20, 2002	FEB	NEWA	
		MEGESTROL ACETATE						
		SUSPENSION; ORAL						
		MEGESTROL ACETATE						
	AB	ROXANE	40MG/ML	N75997 001	FEB 15, 2002	FEB	NEWA	
		MENOTROPINS (FSH;LH)						
		INJECTABLE; INJECTION						
>D>		PERGONAL						
>D>	BX +	SERONO	75 IU/AMP;75 IU/AMP	N17646 001		JUN	DISC	
>A>		@	75 IU/AMP;75 IU/AMP	N17646 001		JUN	DISC	
>D>	BX +		150 IU/AMP;150 IU/AMP	N17646 002	MAY 20, 1985	JUN	DISC	
>A>		@	150 IU/AMP;150 IU/AMP	N17646 002	MAY 20, 1985	JUN	DISC	
		REPRONEX						
>D>	BX	FERRING	75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999	JUN	CRLD	
>A>	+		75 IU/VIAL;75 IU/VIAL	N21047 001	AUG 27, 1999	JUN	CRLD	

>D>	BX		150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999	JUN	CRLD
>A>		+	150 IU/VIAL;150 IU/VIAL	N21047 002	AUG 27, 1999	JUN	CRLD
		MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE					
>D>		INJECTABLE; INJECTION					
>D>		MEPERGAN					
>D>		+ WYETH AYERST	25MG/ML;25MG/ML	N11730 001		JUN	DISC
>A>		@	25MG/ML;25MG/ML	N11730 001		JUN	DISC
		MEPHENTERMINE SULFATE					
>D>		INJECTABLE; INJECTION					
>D>		WYAMINE SULFATE					
>D>		+ WYETH AYERST	EQ 15MG BASE/ML	N08248 002		JUN	DISC
>A>		@	EQ 15MG BASE/ML	N08248 002		JUN	DISC
		MEPHENYTOIN					
>D>		TABLET; ORAL					
>D>		MESANTOIN					
>D>		+ NOVARTIS	100MG	N06008 001		JUN	DISC
>A>		@	100MG	N06008 001		JUN	DISC
		MEQUINOL; TRETINOIN					
		SOLUTION; TOPICAL					
		SOLAGE					
		+ GALDERMA LABS	2%;0.01%	N20922 001	DEC 10, 1999	APR	CAHN
		MESNA					
		INJECTABLE; INTRAVENOUS					
		MESNEX					
	AP	+ BAXTER HLTHCARE	100MG/ML	N19884 001	DEC 30, 1988	MAR	CAHN
		TABLET; ORAL					
>A>		+ BAXTER HLTHCARE	400MG	N20855 001	MAR 21, 2002	JUN	CAHN
>D>		+ BRISTOL MYERS SQUIBB	400MG	N20855 001	MAR 21, 2002	JUN	CAHN
		+	400MG	N20855 001	MAR 21, 2002	MAR	NEWA
		MESORIDAZINE BESYLATE					
>D>		INJECTABLE; INJECTION					
>D>		SERENTIL					
>D>		+ NOVARTIS	EQ 25MG BASE/ML	N16775 001		JUN	DISC
>A>		@	EQ 25MG BASE/ML	N16775 001		JUN	DISC
		MESTRANOL; NORETHINDRONE					
		TABLET; ORAL-28					
		NORINYL 1+50 28-DAY					
	AB	WATSON LABS	0.05MG;1MG	N16659 001		JAN	CAHN
		METAPROTERENOL SULFATE					
		SOLUTION; INHALATION					
		ALUPENT					
>D>		+ BOEHRINGER INGELHEIM	5%	N17659 001		JUN	DISC
>A>		@	5%	N17659 001		JUN	DISC
		METAPROTERENOL SULFATE					
	AN	MORTON GROVE	0.4%	N75586 001	MAY 30, 2002	MAY	NEWA

AN		0.6%	N75586 002	MAY 30, 2002	MAY	NEWA

METAXALONE
TABLET; ORAL
SKELAXIN

>D>	+ CARNRICK	400MG	N13217 001		JUN	CAHN
>A>	+ ELAN PHARMS	400MG	N13217 001		JUN	CAHN

METFORMIN HYDROCHLORIDE
TABLET; ORAL
GLUCOPHAGE

AB	BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995	JAN	CFTG
AB		850MG	N20357 002	MAR 03, 1995	JAN	CFTG
AB +		1GM	N20357 005	NOV 05, 1998	JAN	CFTG

METFORMIN HCL

AB	ALPHAPHARM	500MG	N75969 001	JAN 29, 2002	JAN	NEWA
AB		850MG	N75969 002	JAN 29, 2002	JAN	NEWA
AB		1GM	N75969 003	JAN 29, 2002	JAN	NEWA
AB	ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75961 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75961 003	JAN 25, 2002	JAN	NEWA
AB	BARR	500MG	N75971 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75971 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75971 003	JAN 25, 2002	JAN	NEWA
AB	CARACO	500MG	N75967 001	JAN 29, 2002	JAN	NEWA
AB		850MG	N75967 002	JAN 29, 2002	JAN	NEWA
AB		1GM	N75967 003	JAN 29, 2002	JAN	NEWA
AB	EON	500MG	N75965 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75965 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75965 003	JAN 25, 2002	JAN	NEWA
AB	GENEVA PHARMS	500MG	N75985 001	JAN 25, 2002	MAY	CAHN
AB		850MG	N75985 002	JAN 25, 2002	MAY	CAHN
AB		1GM	N75985 003	JAN 25, 2002	MAY	CAHN
AB	GENEVA PHARMS TECH	500MG	N75985 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75985 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75985 003	JAN 25, 2002	JAN	NEWA
AB	GENPHARM	500MG	N75973 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75973 002	JAN 25, 2002	JAN	NEWA
AB		1GM	N75973 003	JAN 25, 2002	JAN	NEWA
AB	GOLDLINE	500MG	N75972 001	JAN 24, 2002	JAN	NEWA
AB		625MG	N75972 005	JAN 24, 2002	JAN	NEWA
AB		750MG	N75972 004	JAN 24, 2002	JAN	NEWA
AB		850MG	N75972 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75972 003	JAN 24, 2002	JAN	NEWA
AB	MUTUAL PHARMA	500MG	N76038 001	FEB 21, 2002	FEB	NEWA
AB		850MG	N76038 002	FEB 21, 2002	FEB	NEWA
AB		1GM	N76038 003	FEB 21, 2002	FEB	NEWA
AB	MYLAN	500MG	N75976 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N75976 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75976 003	JAN 24, 2002	JAN	NEWA
AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002	JAN	NEWA
AB		850MG	N76033 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N76033 003	JAN 24, 2001	JAN	NEWA

	AB	TEVA	500MG	N75978 001	JAN 25, 2002	JAN	NEWA
	AB		850MG	N75978 002	JAN 25, 2002	JAN	NEWA
	AB	TORPHARM	500MG	N75984 001	APR 23, 2002	APR	NEWA
	AB		850MG	N75984 002	APR 23, 2002	APR	NEWA
	AB		1GM	N75984 003	APR 23, 2002	APR	NEWA
	AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75979 002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75979 003	JAN 24, 2002	JAN	NEWA
	AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002	JAN	NEWA
	AB		625MG	N75975 004	JAN 24, 2002	JAN	NEWA
	AB		750MG	N75975 005	JAN 24, 2002	JAN	NEWA
	AB		850MG	N75975 002	JAN 24, 2002	JAN	NEWA
	AB		1GM	N75975 003	JAN 24, 2002	JAN	NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

>D>		+	ABBOTT	5MG	N05378 004		JUN	DISC
>A>		@		5MG	N05378 004		JUN	DISC
>D>		+		10MG	N05378 003		JUN	DISC
>A>		@		10MG	N05378 003		JUN	DISC
>D>		+		15MG	N05378 005		JUN	DISC
>A>		@		15MG	N05378 005		JUN	DISC

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

		+	KING PHARMS	500MG/VIAL	N11559 001		FEB	CAHN
		+		2.5GM/VIAL	N11559 002		FEB	CAHN
		+		5GM/VIAL	N11559 003		FEB	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX

>D>	AP		PHARMACIA AND UPJOHN	EQ 50MG BASE/VIAL	N87695 002	APR 08, 1983	JUN	CRLD
>A>		+		EQ 50MG BASE/VIAL	N87695 002	APR 08, 1983	JUN	CRLD
>D>	AP			EQ 100MG BASE/VIAL	N87695 003	APR 08, 1983	JUN	CRLD
>A>		+		EQ 100MG BASE/VIAL	N87695 003	APR 08, 1983	JUN	CRLD

METHOTREXATE SODIUM

>D>		+	LEDERLE	EQ 2.5MG BASE/ML	N11719 004		JUN	DISC
>A>		@		EQ 2.5MG BASE/ML	N11719 004		JUN	DISC
>D>	AP	+		EQ 50MG BASE/VIAL	N11719 003		JUN	DISC
>A>		@		EQ 50MG BASE/VIAL	N11719 003		JUN	DISC
>D>	AP	+		EQ 100MG BASE/VIAL	N11719 006		JUN	DISC
>A>		@		EQ 100MG BASE/VIAL	N11719 006		JUN	DISC

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

>D>		+	MERCK	250MG/5ML	N18389 001		JUN	DISC
>A>		@		250MG/5ML	N18389 001		JUN	DISC

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

>D>		+	CELLTECH PHARMS	20MG	N21259	001	APR 03, 2001	JUN	CTEC
>A>	BX	+		20MG	N21259	001	APR 03, 2001	JUN	CTEC

RITALIN LA

>A>	BX		NOVARTIS	20MG	N21284	001	JUN 05, 2002	JUN	NEWA
>A>				30MG	N21284	002	JUN 05, 2002	JUN	NEWA
>A>		+		40MG	N21284	003	JUN 05, 2002	JUN	NEWA

TABLET; ORAL
METHYLPHENIDATE HCL

	AB		PUREPAC PHARM	5MG	N40321	001	FEB 05, 2002	FEB	NEWA
	AB			10MG	N40321	002	FEB 05, 2002	FEB	NEWA
	AB			20MG	N40321	003	FEB 05, 2002	FEB	NEWA

TABLET, EXTENDED RELEASE; ORAL
CONCERTA

>A>		+	ALZA	27MG	N21121	004	APR 01, 2002	JUN	NEWA

METHYLPREDNISOLONE
TABLET; ORAL
METHYLPREDNISOLONE

	AB		GENEVA PHARMS	4MG	N40194	001	OCT 31, 1997	MAY	CAHN

MICONAZOLE NITRATE
CREAM, INSERT; TOPICAL, VAGINAL
MONISTAT DUAL- PAK

>D>		+	PERSONAL PRODS	1.2GM;2%	N20968	001	JUN 30, 1999	JUN	DISC
>A>		@		1.2GM;2%	N20968	001	JUN 30, 1999	JUN	DISC

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

>A>	AP		ROSS LABS	EQ 1MG BASE/ML	N75856	001	JUN 13, 2002	JUN	NEWA
>A>	AP			EQ 5MG BASE/ML	N75856	002	JUN 13, 2002	JUN	NEWA

SYRUP; ORAL

	AA		RANBAXY	EQ 2MG BASE/ML	N76058	001	MAR 15, 2002	MAR	NEWA
	AA		ROXANE	EQ 2MG BASE/ML	N75873	001	APR 30, 2002	APR	NEWA

VERSED

	AA	+	ROCHE	EQ 2MG BASE/ML	N20942	001	OCT 15, 1998	MAR	CFTG

MIDODRINE HYDROCHLORIDE
TABLET; ORAL
PROAMATINE

>A>		+	SHIRE LABS	10MG	N19815	003	MAR 20, 2002	JUN	NEWA
>D>		+	SHIRE PHARM	5MG	N19815	002	SEP 06, 1996	JUN	CRLD
>A>				5MG	N19815	002	SEP 06, 1996	JUN	CRLD

MILRINONE LACTATE
INJECTABLE; INJECTION
MILRINONE LACTATE

>A>									
	AP		ABBOTT	EQ 1MG BASE/ML	N75884	001	MAY 28, 2002	MAY	NEWA
	AP		AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936	001	MAY 28, 2002	MAY	NEWA

	AP		BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEWA
	AP		BEDFORD	EQ 1MG BASE/ML	N75660 001	MAY 28, 2002	MAY	NEWA
	AP			EQ 20MG /20ML (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEWA
	AP			EQ 50MG /50ML (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEWA
	AP		ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEWA
	AP		FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEWA
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP		ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEWA
	AP	+		EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEWA
	AP		BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEWA
	AP			EQ 40MG BASE/200ML	N75834 002	MAY 28, 2002	JUN	NEWA
	AP			EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEWA
	AP		ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEWA
		PRIMACOR						
	AP	+	SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG
		PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER						
	AP		SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG
>D>	AP	+		EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG
>A>	AP	+		EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG
	AP	+		EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG
	MINOCYCLINE HYDROCHLORIDE							
>D>	SUSPENSION; ORAL							
>D>	MINOCIN							
>D>	+	LEDERLE		EQ 50MG BASE/5ML	N50445 001		JUN	DISC
>A>	@			EQ 50MG BASE/5ML	N50445 001		JUN	DISC
	MIVACURIUM CHLORIDE							
	INJECTABLE; INJECTION							
	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+	ABBOTT		EQ 0.5MG BASE/ML	N20098 002	JAN 22, 1992	JUN	DISC
>A>	@			EQ 0.5MG BASE/ML	N20098 002	JAN 22, 1992	JUN	DISC
	MOMETASONE FUROATE							
	OINTMENT; TOPICAL							
	ELOCON							
AB	+	SCHERING		0.1%	N19543 001	APR 30, 1987	MAR	CFTG
	MOMETASONE FUROATE							
AB		CLAY PARK		0.1%	N76067 001	MAR 18, 2002	MAR	NEWA
	MONOCTANOIN							
>D>	LIQUID; PERFUSION, BILIARY							
>D>	MOCTANIN							
>D>		ETHITEK		100%	N19368 001	OCT 29, 1985	JUN	DISC
>A>	@			100%	N19368 001	OCT 29, 1985	JUN	DISC
	MORPHINE SULFATE							
	CAPSULE, EXTENDED RELEASE; ORAL							
	AVINZA							
		ELAN PHARM		30MG	N21260 001	MAR 20, 2002	MAR	NEWA
				60MG	N21260 002	MAR 20, 2002	MAR	NEWA
				90MG	N21260 003	MAR 20, 2002	MAR	NEWA
	+			120MG	N21260 004	MAR 20, 2002	MAR	NEWA

NABUMETONE
TABLET; ORAL
NABUMETONE

AB	EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
AB		750MG	N75280 002	FEB 25, 2002	FEB	NEWA
AB	INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
AB		750MG	N75590 002	FEB 25, 2002	FEB	NEWA

NAFCILLIN SODIUM

>D>	CAPSULE; ORAL						
>D>	UNIPEN						
>D>	+ WYETH AYERST	EQ 250MG BASE	N50111 001			JUN	DISC
>A>	@	EQ 250MG BASE	N50111 001			JUN	DISC

NALIDIXIC ACID

>D>	SUSPENSION; ORAL						
>D>	NEGGRAM						
>D>	+ SANOFI SYNTHELABO	250MG/5ML	N17430 001			JUN	DISC
>A>	@	250MG/5ML	N17430 001			JUN	DISC

NALTREXONE HYDROCHLORIDE
TABLET; ORAL
NALTREXONE HCL

	MALLINCKRODT	25MG	N76264 001	MAR 22, 2002	MAR	NEWA
AB		50MG	N76264 002	MAR 22, 2002	MAR	NEWA
+		100MG	N76264 003	MAR 22, 2002	MAR	NEWA

NAPROXEN SODIUM
TABLET, EXTENDED RELEASE; ORAL
NAPRELAN

>D>	+ ELAN PHARM	EQ 750MG BASE	N20353 003	JAN 05, 1996	JUN	DISC
>A>	@	EQ 750MG BASE	N20353 003	JAN 05, 1996	JUN	DISC

NEOMYCIN SULFATE
SOLUTION; ORAL

>D>	MYCIFRADIN						
>D>	AA + PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N50285 001			JUN	DISC
>A>	@	EQ 87.5MG BASE/5ML	N50285 001			JUN	DISC
	AA +	EQ 87.5MG BASE/5ML	N50285 001			MAY	CFTG
	NEO-FRADIN						
>D>	AA PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	JUN	CRLD
>A>	+	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	JUN	CRLD
	AA	EQ 87.5MG BASE/5ML	N65010 001	MAY 23, 2002	MAY	NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

>D>	OINTMENT; OPHTHALMIC						
>D>	STATROL						
>D>	+ ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50344 002			JUN	DISC
>A>	@	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50344 002			JUN	DISC
>D>	SOLUTION/DROPS; OPHTHALMIC						
>D>	+ ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N50456 001			JUN	DISC
>A>	@	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N50456 001			JUN	DISC

NIACIN
TABLET, EXTENDED RELEASE; ORAL
NIASPAN

>D>	+ KOS	500MG	N20381	002	JUL 28, 1997	JUN	DISC
>A>	@	500MG	N20381	002	JUL 28, 1997	JUN	DISC

NIASPAN TITRATION STARTER PACK

>D>	+ KOS	375MG;500MG;750MG	N20381	005	JUL 28, 1997	JUN	DISC
>A>	@	375MG;500MG;750MG	N20381	005	JUL 28, 1997	JUN	DISC

NILUTAMIDE
TABLET; ORAL
NILANDRON

>D>	AVENTIS PHARMS	50MG	N20169	001	SEP 19, 1996	JUN	DISC
>A>	@	50MG	N20169	001	SEP 19, 1996	JUN	DISC
>D>	+	150MG	N20169	002	APR 30, 1999	JUN	DISC
>A>	@	150MG	N20169	002	APR 30, 1999	JUN	DISC

NISOLDIPINE
TABLET, EXTENDED RELEASE; ORAL
SULAR

+	FIRST HORIZON	10MG	N20356	001	FEB 02, 1995	MAR	CAHN
		20MG	N20356	002	FEB 02, 1995	MAR	CAHN
+		30MG	N20356	003	FEB 02, 1995	MAR	CAHN
+		40MG	N20356	004	FEB 02, 1995	MAR	CAHN
+	WHITEHALL ROBINS	10MG	N20356	001	FEB 02, 1995	FEB	CAHN
		20MG	N20356	002	FEB 02, 1995	FEB	CAHN
+		40MG	N20356	004	FEB 02, 1995	FEB	CAHN

NITISINONE
CAPSULE; ORAL
ORFADIN

	R R REGISTRATIONS	2MG	N21232	001	JAN 18, 2002	JAN	NEWA
		5MG	N21232	002	JAN 18, 2002	JAN	NEWA
+		10MG	N21232	003	JAN 18, 2002	JAN	NEWA
	SWEDISH ORPHAN	2MG	N21232	001	JAN 18, 2002	MAY	CAHN
		5MG	N21232	002	JAN 18, 2002	MAY	CAHN
+		10MG	N21232	003	JAN 18, 2002	MAY	CAHN

NITROFURANTOIN
SUSPENSION; ORAL
FURADANTIN

+	FIRST HORIZON	25MG/5ML	N09175	001		JAN	CAHN

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL

>D>	@ FIRST HORIZON	0.4MG/SPRAY	N18705	001	OCT 31, 1985	JUN	CAHN
	@	0.4MG/SPRAY	N18705	001	OCT 31, 1985	APR	CAHN
>A>	@ POHL BOSKAMP	0.4MG/SPRAY	N18705	001	OCT 31, 1985	JUN	CAHN

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY

>D>	+ FIRST HORIZON	0.4MG/SPRAY	N18705	002	JAN 10, 1997	JUN	CAHN

		+		0.4MG/SPRAY	N18705 002	JAN 10, 1997	APR	CAHN
>A>		+	POHL BOSKAMP	0.4MG/SPRAY	N18705 002	JAN 10, 1997	JUN	CAHN
		TABLET; SUBLINGUAL						
		NITROSTAT						
>D>			PARKE DAVIS	0.4MG	N21134 002	MAY 01, 2000	JUN	CAHN
>A>			PFIZER PHARMS	0.4MG	N21134 002	MAY 01, 2000	JUN	CAHN
	NORETHINDRONE							
	TABLET; ORAL							
	NOR-QD							
	+		WATSON LABS (UTAH)	0.35MG	N17060 001		MAY	CAHN
	NORTRIPTYLINE HYDROCHLORIDE							
	SOLUTION; ORAL							
	AVENTYL HCL							
>D>	AA	+	LILLY	EQ 10MG BASE/5ML	N14685 001		JUN	CAHN
>A>	AA	+	RANBAXY	EQ 10MG BASE/5ML	N14685 001		JUN	CAHN
	NOVOBIOCIN SODIUM							
>D>		CAPSULE; ORAL						
>D>		ALBAMYCIN						
>D>		+	PHARMACIA AND UPJOHN	EQ 250MG BASE	N50339 001		JUN	DISC
>A>		@		EQ 250MG BASE	N50339 001		JUN	DISC
	NYSTATIN							
	TABLET; ORAL							
>D>		NILSTAT						
>D>	AA		LEDERLE	500,000 UNITS	N61151 001		JUN	DISC
>A>		@		500,000 UNITS	N61151 001		JUN	DISC
	OFLOXACIN							
	INJECTABLE; INJECTION							
	FLOXIN							
	AP	+	JOHNSON RW	40MG/ML	N20087 003	MAR 31, 1992	JAN	CFTG
	OFLOXACIN							
	AP		BEDFORD	40MG/ML	N75762 001	JAN 16, 2002	JAN	NEWA
	OLMESARTAN MEDOXOMIL							
	TABLET; ORAL							
	BENICAR							
			SANKYO	5MG	N21286 001	APR 25, 2002	APR	NEWA
				20MG	N21286 003	APR 25, 2002	APR	NEWA
		+		40MG	N21286 004	APR 25, 2002	APR	NEWA
	OXANDROLONE							
	TABLET; ORAL							
	OXANDRIN							
>D>		+	BIO TECH GEN	2.5MG	N13718 001		JUN	CRLD
>A>				2.5MG	N13718 001		JUN	CRLD
>A>		+		10MG	N13718 002	NOV 05, 2001	JUN	NEWA

OXAPROZIN
TABLET; ORAL
OXAPROZIN

AB	CARACO	600MG	N75844 001	JAN 03, 2002	JAN	NEWA
AB	IVAX PHARMS	600MG	N75846 001	MAY 13, 2002	MAY	NEWA

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL

AP	ABBOTT	6MG/ML	N76131 001	MAY 08, 2002	MAY	NEWA

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP	AESGEN	30MG/VIAL	N75594 001	MAY 06, 2002	MAY	NEWA
AP		90MG/VIAL	N75594 002	MAY 06, 2002	MAY	NEWA
AP	AM PHARM PARTNERS	30MG/VIAL	N75773 001	MAY 06, 2002	MAY	NEWA
AP		30MG /10ML(3MG/ML)	N76207 001	MAY 17, 2002	MAY	NEWA
AP		90MG/VIAL	N75773 002	MAY 06, 2002	MAY	NEWA
AP		90MG /10ML(9MG/ML)	N76207 002	MAY 17, 2002	MAY	NEWA
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAY	CDFR
AP +		90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAY	CDFR
>A> AP	FAULDING	30MG /10ML(3MG/ML)	N75841 001	JUN 27, 2002	JUN	NEWA
>A> AP		60MG /10ML(6MG/ML)	N75841 002	JUN 27, 2002	JUN	NEWA
>A> AP		90MG /10ML(9MG/ML)	N75841 003	JUN 27, 2002	JUN	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAY	CDFR
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDFR
INJECTABLE; IV (INFUSION)						
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEWA
AP +		90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEWA
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
>D> CAPSULE; ORAL
>D> COTAZYM

>D> +	ORGANON	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N20580 001	DEC 09, 1996	JUN	DISC
>A>	@	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N20580 001	DEC 09, 1996	JUN	DISC

PARAMETHADIONE
>D> CAPSULE; ORAL
>D> PARADIONE

>D> +	ABBOTT	150MG	N06800 003		JUN	DISC
>A>	@	150MG	N06800 003		JUN	DISC
>D>		300MG	N06800 001		JUN	DISC
>A>	@	300MG	N06800 001		JUN	DISC

PENICILLIN V POTASSIUM
FOR SOLUTION; ORAL
PEN-VEE K

	@ WYETH AYERST	EQ 125MG BASE/5ML	N60007 001		MAY	DISC
	@	EQ 250MG BASE/5ML	N60007 002		MAY	DISC

PENTAGASTRIN
INJECTABLE; INJECTION
PEPTAVLON

	@ WYETH AYERST	0.25MG/ML	N17048 001		APR	DISC

PHENACEMIDE
TABLET; ORAL
PHENURONE

>D>	+ ABBOTT	500MG	N07707 001		JUN	DISC
>A>	@	500MG	N07707 001		JUN	DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
>D> TABLET; ORAL
>D> SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL

>A>	@ ABLE	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	DISC
>D>	+	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	DISC

PHENDIMETRAZINE TARTRATE
TABLET; ORAL
PHENDIMETRAZINE TARTRATE

AA	MIKART	35MG	N89452 001	OCT 30, 1991	MAR	CMFD

PHENTERMINE HYDROCHLORIDE
CAPSULE; ORAL
PHENTERMINE HCL

AA	VINTAGE PHARMS	37.5MG	N40377 001	JAN 04, 2002	JAN	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE
>D> SOLUTION/DROPS; OPHTHALMIC
>D> PREFRIN-A

>D>	ALLERGAN	0.12%;0.1%	N07953 001		JUN	DISC
>A>	@	0.12%;0.1%	N07953 001		JUN	DISC

PHENYTOIN
SUSPENSION; ORAL
PHENTYTOIN

AB	MORTON GROVE	125MG/5ML	N40420 001	APR 19, 2002	APR	NEWA

PILOCARPINE
>D> DRUG DELIVERY SYSTEM; OPHTHALMIC
>D> OCUSERT PILO-40

>D>	+ AKORN	11MG	N17548 001		JUN	DISC
>A>	@	11MG	N17548 001		JUN	DISC

>D> INSERT, EXTENDED RELEASE; OPHTHALMIC
>D> OCUSERT PILO-20

>D>	+ AKORN	5MG	N17431 001		JUN	DISC

>A>		@	5MG	N17431 001		JUN	DISC
		PIPECURONIUM BROMIDE					
>D>		INJECTABLE; INJECTION					
>D>		ARDUAN					
>D>	+	ORGANON	10MG/VIAL	N19638 001	JUN 26, 1990	JUN	DISC
>A>		@	10MG/VIAL	N19638 001	JUN 26, 1990	JUN	DISC
		PODOFILOX					
		SOLUTION; TOPICAL					
		CONDYLOX					
AT	+	PADDOCK	0.5%	N19795 001	DEC 13, 1990	JAN	CFTG
		PODOFILOX					
AT		PADDOCK	0.5%	N75600 001	JAN 29, 2002	JAN	NEWA
		POTASSIUM CHLORIDE					
		TABLET, EXTENDED RELEASE; ORAL					
		POTASSIUM CHLORIDE					
AB		ANDRX PHARMS	10MEQ	N75604 001	APR 10, 2002	APR	NEWA
AB			20MEQ	N75604 002	APR 10, 2002	APR	NEWA
AB		KV PHARM	20MEQ	N76044 001	APR 05, 2002	APR	NEWA
		PRAVASTATIN SODIUM					
		TABLET; INJECTION					
		PRAVACHOL					
	+	BRISTOL MYERS SQUIBB	80MG	N19898 008	DEC 18, 2001	MAR	NEWA
		TABLET; ORAL					
		BRISTOL MYERS SQUIBB	40MG	N19898 004	MAR 22, 1993	MAR	CRLD
	+		80MG	N19898 008	DEC 18, 2001	APR	CDFR
		PREDNICARBATE					
		CREAM; TOPICAL					
		DERMATOP					
>D>	+	AVENTIS PHARMS	0.1%	N20279 001	OCT 29, 1993	JUN	CAHN
>A>	+	DERMIK LABS	0.1%	N20279 001	OCT 29, 1993	JUN	CAHN
		OINTMENT; TOPICAL					
>D>	+	AVENTIS PHARMS	0.1%	N19568 001	SEP 23, 1991	JUN	CAHN
>A>	+	DERMIK LABS	0.1%	N19568 001	SEP 23, 1991	JUN	CAHN
		PREDNISOLONE					
		SYRUP; ORAL					
		PREDNISOLONE					
AA		KV PHARM	15MG/5ML	N40364 001	APR 10, 2002	APR	NEWA
		PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM					
		SUSPENSION; OPHTHALMIC					
>D>		ISOPTO CETAPRED					
>D>	+	ALCON	0.25%;10%	N87547 001		JUN	DISC
>A>		@	0.25%;10%	N87547 001		JUN	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

>D>		+	CELLTECH PHARMS	EQ 5MG BASE/5ML	N19157 001	MAY 28, 1986	JUN	CFTG
>A>	AA	+		EQ 5MG BASE/5ML	N19157 001	MAY 28, 1986	JUN	CFTG

PREDNISOLONE SODIUM PHOSPHATE

>A>	AA		MORTON GROVE	EQ 5MG BASE/5ML	N75099 001	JUN 28, 2002	JUN	NEWA

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

>D>		+	MERCK	20MG/ML	N10562 001		JUN	DISC
>A>			@	20MG/ML	N10562 001		JUN	DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

>D>		+	GLAXOSMITHKLINE	EQ 10MG BASE	N11000 001		JUN	DISC
>A>			@	EQ 10MG BASE	N11000 001		JUN	DISC
>D>				EQ 10MG BASE	N21019 001	OCT 06, 1999	JUN	CRLD
>A>		+		EQ 10MG BASE	N21019 001	OCT 06, 1999	JUN	CRLD
>D>		+		EQ 15MG BASE	N11000 002		JUN	DISC
>A>			@	EQ 15MG BASE	N11000 002		JUN	DISC
>D>				EQ 15MG BASE	N21019 002	OCT 06, 1999	JUN	CRLD
>A>		+		EQ 15MG BASE	N21019 002	OCT 06, 1999	JUN	CRLD
>D>		+		EQ 30MG BASE	N11000 003		JUN	DISC
>A>			@	EQ 30MG BASE	N11000 003		JUN	DISC

PROGESTERONE

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

>D>			ALZA	38MG	N17553 001		JUN	DISC
>A>			@	38MG	N17553 001		JUN	DISC

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

>D>		+	WYETH AYERST	50MG/ML	N10349 006		JUN	DISC
>A>			@	50MG/ML	N10349 006		JUN	DISC

TABLET; ORAL

>D>			WYETH AYERST	25MG	N10348 001		JUN	DISC
>A>			@	25MG	N10348 001		JUN	DISC
>D>		+		50MG	N10348 002		JUN	DISC
>A>			@	50MG	N10348 002		JUN	DISC

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

	AB	+	WYETH AYERST	25MG	N10926 001		FEB	CTEC

PROMETHAZINE HCL

	AB		G AND W LABS	25MG	N40428 001	FEB 05, 2002	FEB	NEWA

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

>D>			SYRUP; ORAL					
>D>			PHENERGAN FORTIS					
>D>		+	WYETH AYERST	25MG/5ML	N08381 003		JUN	DISC
>A>			@	25MG/5ML	N08381 003		JUN	DISC

PROPAFENONE HYDROCHLORIDE

			TABLET; ORAL					
			PROPAFENONE HCL					
	AB		KV PHARM	150MG	N76193 001	FEB 07, 2002	FEB	NEWA
	AB			225MG	N76193 002	FEB 07, 2002	FEB	NEWA
	AB			300MG	N76193 003	FEB 07, 2002	FEB	NEWA

PROPOXYPHENE HYDROCHLORIDE

			CAPSULE; ORAL					
			DARVON					
>A>	AA	+	AAI PHARMA	32MG	N10997 001		JUN	CAHN
>A>	AA	+		65MG	N10997 003		JUN	CAHN
>D>	AA	+	LILLY	32MG	N10997 001		JUN	CAHN
>D>	AA	+		65MG	N10997 003		JUN	CAHN

PROPOXYPHENE NAPSYLATE

			SUSPENSION; ORAL					
			DARVON-N					
>D>		+	LILLY	50MG/5ML	N16861 001		JUN	CAHN
>A>		+	NEOSAN PHARMS	50MG/5ML	N16861 001		JUN	CAHN
			TABLET; ORAL					
>A>		+	AAIPHARMA LLC	100MG	N16862 002		JUN	CAHN
>D>		+	LILLY	100MG	N16862 002		JUN	CAHN

PROPRANOLOL HYDROCHLORIDE

			TABLET; ORAL					
			PROPRANOLOL HCL					
			@ LEDERLE	60MG	N71495 001	DEC 31, 1987	FEB	DISC
			@	80MG	N70128 001	JUL 30, 1985	MAY	CAHN
			@	90MG	N71496 001	DEC 31, 1987	FEB	DISC
			@ PUREPAC PHARM	10MG	N70814 001	NOV 03, 1986	MAY	DISC
			@	20MG	N70815 001	NOV 03, 1986	MAY	DISC
			@	40MG	N70816 001	NOV 03, 1986	MAY	DISC
			@	60MG	N70817 001	NOV 03, 1986	MAY	DISC
			@	80MG	N70757 001	NOV 03, 1986	MAY	DISC

QUINETHAZONE

			TABLET; ORAL					
			HYDROMOX					
			@ LEDERLE	50MG	N13264 001		APR	DISC

RABEPRAZOLE SODIUM

			TABLET, DELAYED RELEASE; ORAL					
			ACIPHEX					
>D>		+	EISAI MEDCL RES	20MG	N20973 002	AUG 19, 1999	JUN	DISC
>A>			@	20MG	N20973 002	AUG 19, 1999	JUN	DISC
		+		20MG	N20973 002	AUG 19, 1999	MAY	CAHN

RAPACURONIUM BROMIDE
INJECTABLE; INJECTION
RAPLON

>D>		ORGANON	100MG/VIAL	N20984	001	AUG 18, 1999	JUN	DISC
>A>		@	100MG/VIAL	N20984	001	AUG 18, 1999	JUN	DISC
>D>	+		200MG/VIAL	N20984	002	AUG 18, 1999	JUN	DISC
>A>		@	200MG/VIAL	N20984	002	AUG 18, 1999	JUN	DISC

RITONAVIR
CAPSULE; ORAL
NORVIR

>D>	+	ABBOTT	100MG	N20680	001	MAR 01, 1996	JUN	DISC
>A>		@	100MG	N20680	001	MAR 01, 1996	JUN	DISC
>D>			100MG	N20945	001	JUN 29, 1999	JUN	CRLD
>A>	+		100MG	N20945	001	JUN 29, 1999	JUN	CRLD

ROCURONIUM BROMIDE
INJECTABLE; INJECTION
ZEMURON

>D>	+	ORGANON	10MG/ML	N20214	002	MAR 17, 1994	JUN	DISC
>A>		@	10MG/ML	N20214	002	MAR 17, 1994	JUN	DISC

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECONAL SODIUM

>D>	+	LILLY	50MG	N86101	001	OCT 03, 1983	JUN	CAHN
>D> AA	+		100MG	N86101	002	OCT 03, 1983	JUN	CAHN
>A>	+	RANBAXY	50MG	N86101	001	OCT 03, 1983	JUN	CAHN
>A> AA	+		100MG	N86101	002	OCT 03, 1983	JUN	CAHN

SECRETIN
FOR SOLUTION; INTRAVENOUS
SECREFLO

	+	CHIRHOCLIN	16UGM/VIAL	N21209	001	APR 04, 2002	APR	NEWA

SELEGILINE HYDROCHLORIDE
CAPSULE; ORAL
SELEGILINE HCL

>A> AB		CLONMEL HLTHCARE	5MG	N75352	001	NOV 30, 1998	JUN	CAHN
>D> AB		ESI LEDERLE	5MG	N75352	001	NOV 30, 1998	JUN	CAHN

TABLET; ORAL

AB		CLONMEL HLTHCARE	5MG	N74641	001	AUG 02, 1996	APR	CAHN

SELENOMETHIONINE, SE-75
INJECTABLE; INJECTION
SELENOMETHIONINE SE 75

>D>	+	CIS	500uCi/ML	N17322	001		JUN	DISC
>A>		@	500uCi/ML	N17322	001		JUN	DISC

SIMETHICONE-CELLULOSE

>D>		SUSPENSION; ORAL					
>D>		SONORX					
>D>	+	BRACCO	7.5MG/ML	N20773 001	OCT 29, 1998	JUN	DISC
>A>		@	7.5MG/ML	N20773 001	OCT 29, 1998	JUN	DISC

SIROLIMUS

>A>		TABLET; ORAL					
>A>		RAPAMUNE					
>A>	+	WYETH AYERST	1MG	N21110 001	AUG 25, 2000	JUN	NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

>D>		SOLUTION; ORAL					
>D>		UCEPHAN					
>D>	+	B BRAUN	100MG/ML;100MG/ML	N19530 001	DEC 23, 1987	JUN	DISC
>A>		@	100MG/ML;100MG/ML	N19530 001	DEC 23, 1987	JUN	DISC

SODIUM IODIDE, I-131

		CAPSULE; ORAL					
		IODOTOPE					
>D>	+	BRACCO	1-150mCi	N10929 003		JUN	DISC
>A>		@	1-150mCi	N10929 003		JUN	DISC
		SOLUTION; ORAL					
>D>	+	BRACCO	7-106mCi/BOT	N10929 002		JUN	DISC
>A>		@	7-106mCi/BOT	N10929 002		JUN	DISC

SOMATROPIN RECOMBINANT

		INJECTABLE; INJECTION					
>A>		NORDITROPIN					
>D>	BX +	NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995	JUN	DISC
>A>		@	4MG/VIAL	N19721 001	MAY 08, 1995	JUN	DISC
>D>	+		8MG/VIAL	N19721 002	MAY 08, 1995	JUN	DISC
>A>		@	8MG/VIAL	N19721 002	MAY 08, 1995	JUN	DISC
>A>		NUTROPIN AQ PEN					
>A>	BX +	GENENTECH	5MG/ML	N20522 002	APR 22, 2002	JUN	NEWA
>A>		SEROSTIM					
>D>	BX	SERONO	4MG/VIAL	N20604 003	JUL 25, 1997	JUN	CRLD
>A>	BX +		4MG/VIAL	N20604 003	JUL 25, 1997	JUN	CRLD
>D>	BX +		6MG/VIAL	N20604 001	AUG 23, 1996	JUN	CRLD
>A>	BX		6MG/VIAL	N20604 001	AUG 23, 1996	JUN	CRLD
>A>		SEROSTIM IN PLASTIC CONTAINER					
>A>	BX +	SERONO	8.8MG/VIAL	N20604 004	SEP 06, 2001	JUN	NEWA
>A>		TEV-TROVIN					
>A>	BX +	BIO TECH GEN	5MG/ML	N19774 002	JAN 04, 2002	JUN	NEWA

SPECTINOMYCIN HYDROCHLORIDE

		INJECTABLE; INJECTION					
		TROBICIN					
>D>	+	PHARMACIA AND UPJOHN	EQ 4GM BASE/VIAL	N50347 002		JUN	DISC
>A>		@	EQ 4GM BASE/VIAL	N50347 002		JUN	DISC

SUCCINYLCHOLINE CHLORIDE
INJECTABLE; INJECTION
QUELICIN PRESERVATIVE FREE

>D>		+ ABBOTT	50MG/ML	N08845 002		JUN	DISC
>A>		@	50MG/ML	N08845 002		JUN	DISC

SULFAMETHIZOLE
TABLET; ORAL
THIOSULFIL

>D>		+ WYETH AYERST	500MG	N08565 004		JUN	DISC
>A>		@	500MG	N08565 004		JUN	DISC

SULFAMETHOXAZOLE
TABLET; ORAL
GANTANOL

		@ ROCHE	500MG	N12715 002		MAY	CTEC

SULFAMETHOXAZOLE; TRIMETHOPRIM
SUSPENSION; ORAL
BACTRIM PEDIATRIC

		@ WOMEN FIRST HLTHCARE	200MG/5ML;40MG/5ML	N17560 002		APR	DISC

SEPTRA

AB	+	MONARCH PHARMS	200MG/5ML;40MG/5ML	N17598 001		APR	CRLD

SULFAPYRIDINE
TABLET; ORAL
SULFAPYRIDINE

>D>		+ LILLY	500MG	N00159 001		JUN	DISC
>A>		@	500MG	N00159 001		JUN	DISC

SULFASALAZINE
TABLET; ORAL
SULFASALAZINE

AB		VINTAGE PHARMS	500MG	N40349 001	JAN 11, 2002	JAN	NEWA

TABLET, DELAYED RELEASE; ORAL
AZULFIDINE EN-TABS

AB	+	PHARMACIA AND UPJOHN	500MG	N07073 002	APR 06, 1983	JAN	CFTG

SULFASALAZINE

AB		VINTAGE PHARMS	500MG	N75339 001	JAN 11, 2002	JAN	NEWA

SULFISOXAZOLE ACETYL
SYRUP; ORAL
GANTRISIN

>D>		+ ROCHE	EQ 500MG BASE/5ML	N09182 002		JUN	DISC
>A>		@	EQ 500MG BASE/5ML	N09182 002		JUN	DISC

SUMATRIPTAN SUCCINATE
TABLET; ORAL
IMITREX

>D>		+ GLAXOSMITHKLINE	EQ 50MG BASE	N20132 003	JUN 01, 1995	JUN	CRLD
>A>			EQ 50MG BASE	N20132 003	JUN 01, 1995	JUN	CRLD
>D>		@	EQ 100MG BASE	N20132 001	JUN 01, 1995	JUN	CMFD

>A>	+	EQ 100MG BASE	N20132 001	JUN 01, 1995	JUN	CMFD	
	SUPROFEN						
>D>	SOLUTION/DROPS; OPHTHALMIC						
>D>	PROFENAL						
>D>	+ ALCON	1%	N19387 001	DEC 23, 1988	JUN	DISC	
>A>	@	1%	N19387 001	DEC 23, 1988	JUN	DISC	
	TECHNETIUM TC-99M ALBUMIN COLLOID KIT						
>D>	INJECTABLE; INJECTION						
>D>	MICROLITE						
>D>	CIS	N/A	N18263 001	MAR 25, 1983	JUN	DISC	
>A>	@	N/A	N18263 001	MAR 25, 1983	JUN	DISC	
	TECHNETIUM TC-99M RED BLOOD CELL KIT						
>D>	INJECTABLE; INJECTION						
>D>	RBC-SCAN						
>D>	CADEMA	N/A	N20063 001	JUN 11, 1992	JUN	DISC	
>A>	@	N/A	N20063 001	JUN 11, 1992	JUN	DISC	
	TECHNETIUM TC-99M SODIUM PERTECHNETATE						
>D>	SOLUTION; INJECTION, ORAL						
>D>	SODIUM PERTECHNETATE TC 99M						
>D>	MALLINCKRODT	10-60mCi/ML	N17725 001		JUN	DISC	
>A>	@	10-60mCi/ML	N17725 001		JUN	DISC	
	TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR						
	SOLUTION; INJECTION, ORAL						
>D>	TECHNETIUM TC 99M GENERATOR						
>D>	AMERSHAM HLTH	830-16600mCi/GENERATOR	N17693 001		JUN	DISC	
>A>	@	830-16600mCi/GENERATOR	N17693 001		JUN	DISC	
	TERBINAFINE						
>D>	GEL; TOPICAL						
>D>	LAMISIL						
>D>	+ NOVARTIS	1%	N20846 001	APR 29, 1998	JUN	DISC	
>A>	@	1%	N20846 001	APR 29, 1998	JUN	DISC	
	TERBUTALINE SULFATE						
	INJECTABLE; INJECTION						
	BRETHINE						
	+ NEOSAN PHARMS	1MG/ML	N18571 001		FEB	CAHN	
	TABLET; ORAL						
AB	NEOSAN PHARMS	2.5MG	N17849 001		FEB	CAHN	
AB	+	5MG	N17849 002		FEB	CAHN	
	TESTOSTERONE						
	FILM, EXTENDED RELEASE; TRANSDERMAL						
	TESTODERM TTS						
BX	+ ALZA	5MG/24HR	N20791 001	DEC 18, 1997	JAN	CTNA	

TETRACYCLINE HYDROCHLORIDE
FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE
\+ ALZA 12.7MG/FIBER N50653 001 MAR 25, 1994 FEB CAHN
>D> INJECTABLE; INJECTION
>D> ACHROMYCIN
>D> + LEDERLE 250MG/VIAL N50273 002 JUN DISC
>A> @ 250MG/VIAL N50273 002 JUN DISC
>D> 500MG/VIAL N50273 003 JUN CRLD
>A> + 500MG/VIAL N50273 003 JUN CRLD
SUSPENSION; ORAL
ACHROMYCIN V
@ LEDERLE 125MG/5ML N50263 002 APR DISC
SUMYCIN
\+ APOTHECON 125MG/5ML N60400 001 APR CTEC
TABLET; ORAL
@ PAR PHARM 50MG N61147 003 MAY CAHN
@ 100MG N61147 002 MAY CAHN
250MG N61147 001 MAY CAHN
\+ 500MG N61147 004 MAY CAHN

THIETHYLPERAZINE MALATE
>D> INJECTABLE; INJECTION
>D> TORECAN
>D> + NOVARTIS 5MG/ML N12754 002 JUN DISC
>A> @ 5MG/ML N12754 002 JUN DISC

THIORIDAZINE
>D> SUSPENSION; ORAL
>D> MELLARIL-S
>D> NOVARTIS EQ 25MG HCL/5ML N17923 001 JUN DISC
>A> @ EQ 25MG HCL/5ML N17923 001 JUN DISC
>D> + EQ 100MG HCL/5ML N17923 002 JUN DISC
>A> @ EQ 100MG HCL/5ML N17923 002 JUN DISC

THIOTEPA
INJECTABLE; INJECTION
THIOTEPA
AP AM PHARM PARTNERS 15MG/VIAL N75698 001 SEP 20, 2001 FEB CAHN

THIOTHIXENE HYDROCHLORIDE
CONCENTRATE; ORAL
THIOTHIXENE HCL INTENSOL
@ ROXANE EQ 5MG BASE/ML N73494 001 JUN 30, 1992 JAN DISC

TIAGABINE HYDROCHLORIDE
TABLET; ORAL
GABITRIL
>D> CEPHALON 16MG N20646 003 SEP 30, 1997 JUN CRLD
>A> + 16MG N20646 003 SEP 30, 1997 JUN CRLD
>D> + 20MG N20646 004 SEP 30, 1997 JUN DISC
>A> @ 20MG N20646 004 SEP 30, 1997 JUN DISC

		TINZAPARIN SODIUM						
		INJECTABLE; INJECTION						
		INNOHEP						
		+ LEO PHARM	20,000 IU/ML	N20484	001	JUL 14, 2000	APR	CAHN
		TIZANIDINE HYDROCHLORIDE						
		TABLET; ORAL						
>A>		TIZANIDINE HCL						
>A>	AB	EON	EQ 4MG BASE	N76280	002	JUN 27, 2002	JUN	NEWA
		ZANAFLEX						
>D>		+ ELAN PHARMS	EQ 4MG BASE	N20397	001	NOV 27, 1996	JUN	CFTG
>A>	AB	+	EQ 4MG BASE	N20397	001	NOV 27, 1996	JUN	CFTG
		TOBRAMYCIN						
		SOLUTION/DROPS; OPHTHALMIC						
		TOBRAMYCIN						
	AT	NOVEX	0.3%	N65087	001	FEB 25, 2002	FEB	NEWA
		TOBRAMYCIN SULFATE						
		INJECTABLE; INJECTION						
		TOBRAMYCIN SULFATE						
		@ ASTRAZENECA	EQ 40MG BASE/ML	N63120	001	OCT 31, 1994	FEB	DISC
		@	EQ 40MG BASE/ML	N63122	001	OCT 31, 1994	JAN	DISC
		TOLAZOLINE HYDROCHLORIDE						
>D>		INJECTABLE; INJECTION						
>D>		PRISCOLINE						
>D>		+ NOVARTIS	25MG/ML	N06403	005	FEB 22, 1985	JUN	DISC
>A>		@	25MG/ML	N06403	005	FEB 22, 1985	JUN	DISC
		TOPIRAMATE						
		TABLET; ORAL						
		TOPAMAX						
		+ JOHNSON AND JOHNSON	25MG	N20505	004	DEC 24, 1996	JAN	CAHN
		@	50MG	N20505	005	DEC 24, 1996	JAN	CAHN
			100MG	N20505	001	DEC 24, 1996	JAN	CAHN
			200MG	N20505	002	DEC 24, 1996	JAN	CAHN
		@	300MG	N20505	003	DEC 24, 1996	JAN	CAHN
		@	400MG	N20505	006	DEC 24, 1996	JAN	CAHN
		TORSEMIDE						
		TABLET; ORAL						
		DEMADEX						
	AB	ROCHE	5MG	N20136	001	AUG 23, 1993	MAY	CFTG
	AB		10MG	N20136	002	AUG 23, 1993	MAY	CFTG
	AB	+	20MG	N20136	003	AUG 23, 1993	MAY	CFTG
	AB		100MG	N20136	004	AUG 23, 1993	MAY	CFTG
		TORSEMIDE						
	AB	TEVA	5MG	N76110	001	MAY 14, 2002	MAY	NEWA
	AB		10MG	N76110	002	MAY 14, 2002	MAY	NEWA
	AB		20MG	N76110	003	MAY 14, 2002	MAY	NEWA
	AB		100MG	N76110	004	MAY 14, 2002	MAY	NEWA

		TRAMADOL HYDROCHLORIDE							
		TABLET; ORAL							
>A>		TRAMADOL HCL							
>A>	AB	CARACO	50MG	N75964	001	JUN 19, 2002	JUN	NEWA	
>A>	AB	COREPHARMA	50MG	N76003	001	JUN 20, 2002	JUN	NEWA	
>A>	AB	EON	50MG	N75968	001	JUN 25, 2002	JUN	NEWA	
>A>	AB	MALLINCKRODT	50MG	N75983	001	JUN 25, 2002	JUN	NEWA	
>A>	AB	MUTUAL PHARM	50MG	N76100	001	JUN 20, 2002	JUN	NEWA	
>A>	AB	MYLAN	50MG	N75986	001	JUN 21, 2002	JUN	NEWA	
>A>	AB	PUREPAC PHARM	50MG	N75960	001	JUN 19, 2002	JUN	NEWA	
>A>	AB	TEVA	50MG	N75977	001	JUN 19, 2002	JUN	NEWA	
>A>	AB	WATSON LABS	50MG	N75962	001	JUN 24, 2002	JUN	NEWA	
>A>		ULTRAM							
>D>	+	JOHNSON AND JOHNSON	50MG	N20281	002	MAR 03, 1995	JUN	CTEC	
	+		50MG	N20281	002	MAR 03, 1995	FEB	CAHN	
	@		100MG	N20281	001	MAR 03, 1995	FEB	CAHN	
>A>	AB +	ORTHO MCNEIL PHARM	50MG	N20281	002	MAR 03, 1995	JUN	CTEC	
		TREPROSTINIL SODIUM							
		INJECTABLE; SUBCUTANEOUS							
		REMODULIN							
		UNITED THERAP	1MG/ML	N21272	001	MAY 21, 2002	MAY	NEWA	
			2.5MG/ML	N21272	002	MAY 21, 2002	MAY	NEWA	
			5MG/ML	N21272	003	MAY 21, 2002	MAY	NEWA	
	+		10MG/ML	N21272	004	MAY 21, 2002	MAY	NEWA	
		TRETINOIN							
		GEL; TOPICAL							
		RETIN-A							
>D>	+	JOHNSON AND JOHNSON	0.01%	N17955	001		JUN	CFTG	
>A>	AB +		0.01%	N17955	001		JUN	CFTG	
>A>		TRETINOIN							
>A>	AB	SPEAR PHARMS	0.01%	N75589	001	JUN 11, 2002	JUN	NEWA	
		TRIAMCINOLONE ACETONIDE							
		INJECTABLE; INJECTION							
		KENALOG-10							
>D>	+	APOTHECON	10MG/ML	N12041	001		JUN	CRLD	
>A>			10MG/ML	N12041	001		JUN	CRLD	
		KENALOG-40							
>D>	BP	APOTHECON	40MG/ML	N14901	001		JUN	CRLD	
>A>	BP +		40MG/ML	N14901	001		JUN	CRLD	
>D>		TRIAMCINOLONE ACETONIDE							
>D>		PARNELL	3MG/ML	N19503	001	OCT 16, 1987	JUN	DISC	
>A>		@	3MG/ML	N19503	001	OCT 16, 1987	JUN	DISC	
		SPRAY, METERED; NASAL							
>D>		TRI-NASAL							
>D>	+	MURO	0.05MG/SPRAY	N20120	001	FEB 04, 2000	JUN	DISC	
>A>		@	0.05MG/SPRAY	N20120	001	FEB 04, 2000	JUN	DISC	

TRIFLUPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
VESPRIN

>D>	+ APOTHECON	10MG/ML	N11325 004		JUN	DISC
>A>	@	10MG/ML	N11325 004		JUN	DISC
>D>	+	20MG/ML	N11325 001		JUN	DISC
>A>	@	20MG/ML	N11325 001		JUN	DISC

TRILOSTANE
CAPSULE; ORAL
MODRASTANE

>A>	@ BIOENVISION	30MG	N18719 002	DEC 31, 1984	JUN	CAHN
>A>	@	60MG	N18719 001	DEC 31, 1984	JUN	CAHN
>D>	@ SANOFI SYNTHELABO	30MG	N18719 002	DEC 31, 1984	JUN	CAHN
>D>	@	60MG	N18719 001	DEC 31, 1984	JUN	CAHN

TRIMETHADIONE

>D>	CAPSULE; ORAL					
>D>	TRIDIONE					
>D>	+ ABBOTT	300MG	N05856 005		JUN	DISC
>A>	@	300MG	N05856 005		JUN	DISC
	SOLUTION; ORAL					
>D>	ABBOTT	200MG/5ML	N05856 002		JUN	DISC
>A>	@	200MG/5ML	N05856 002		JUN	DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE
CAPSULE; ORAL
TIGAN

+	KING PHARMS	300MG	N17531 006	DEC 13, 2001	JAN	NEWA

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL

@	STERIS	100MG/ML	N87939 001	DEC 28, 1982	FEB	DISC

TRIOXSALEN

>D>	TABLET; ORAL					
>D>	TRISORALEN					
>D>	+ ICN	5MG	N12697 001		JUN	DISC
>A>	@	5MG	N12697 001		JUN	DISC

TRIPELENNAMINE CITRATE

>D>	ELIXIR; ORAL					
>D>	PBZ					
>D>	NOVARTIS	EQ 25MG HCL/5ML	N05914 004		JUN	DISC
>A>	@	EQ 25MG HCL/5ML	N05914 004		JUN	DISC

TRIPELENNAMINE HYDROCHLORIDE

>D>	TABLET, EXTENDED RELEASE; ORAL					
>D>	PBZ-SR					
>D>	NOVARTIS	100MG	N10533 001		JUN	DISC
>A>	@	100MG	N10533 001		JUN	DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
>D> TABLET; VAGINAL
>D> SULTRIN
>D> @ ORTHO MCNEIL PHARM 184MG;143.75MG;172.5MG N05794 002 JUN DISC
>A> @ 184MG;143.75MG;172.5MG N05794 002 JUN DISC

UROFOLLITROPIN
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE
BX + FERRING 75 IU/VIAL N21289 001 MAY 06, 2002 MAY NEWA
INJECTABLE; SUBCUTANEOUS
FERTINEX
BX + SERONO 75 IU/AMP N19415 005 AUG 23, 1996 MAY CTEC
>D> 150 IU/AMP N19415 004 AUG 23, 1996 JUN DISC
>A> @ 150 IU/AMP N19415 004 AUG 23, 1996 JUN DISC

URSODIOL
CAPSULE; ORAL
ACTIGALL
@ WATSON PHARMS 150MG N19594 001 DEC 31, 1987 FEB CAHN
AB + 300MG N19594 002 DEC 31, 1987 FEB CAHN

VALACYCLOVIR HYDROCHLORIDE
TABLET; ORAL
VALTREX
@ GLAXOSMITHKLINE EQ 500MG BASE N20487 001 JUN 23, 1995 MAR DISC
@ EQ 1GM BASE N20487 002 JUN 23, 1995 MAR DISC

VALSARTAN
>D> CAPSULE; ORAL
>D> DIOVAN
>D> NOVARTIS 80MG N20665 001 DEC 23, 1996 JUN DISC
>A> @ 80MG N20665 001 DEC 23, 1996 JUN DISC
>D> + 160MG N20665 002 DEC 23, 1996 JUN DISC
>A> @ 160MG N20665 002 DEC 23, 1996 JUN DISC

VECURONIUM BROMIDE
INJECTABLE; INJECTION
NORCURON
>D> AP + ORGANON 20MG/VIAL N18776 003 JAN 03, 1992 JUN DISC
>A> + @ 20MG/VIAL N18776 003 JAN 03, 1992 JUN DISC

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR
WYETH AYERST EQ 37.5MG BASE N20699 001 OCT 20, 1997 MAY CRLD
EQ 150MG BASE N20699 004 OCT 20, 1997 MAY CRLD

VERAPAMIL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
AB + ELAN DRUG 120MG N19614 001 MAY 29, 1990 APR CAHN

AB	+	180MG	N19614 003	JAN 09, 1992	APR	CAHN
AB	+	240MG	N19614 002	MAY 29, 1990	APR	CAHN
	+	360MG	N19614 004	MAY 10, 1996	APR	CAHN

VORICONAZOLE
INJECTABLE; IV (INFUSION)
VFEND
+ PFIZER 200MG/VIAL N21267 001 MAY 24, 2002 MAY NEWA
TABLET; ORAL
PFIZER 50MG N21266 001 MAY 24, 2002 MAY NEWA
+ 200MG N21266 002 MAY 24, 2002 MAY NEWA

XENON, XE-127
>D> GAS; INHALATION
>D> XENON XE 127
>D> MALLINCKRODT 5mCi/VIAL N18536 001 OCT 01, 1982 JUN DISC
>A> @ 5mCi/VIAL N18536 001 OCT 01, 1982 JUN DISC
>D> 10mCi/VIAL N18536 002 OCT 01, 1982 JUN DISC
>A> @ 10mCi/VIAL N18536 002 OCT 01, 1982 JUN DISC

ZILEUTON
TABLET; ORAL
ZYFLO
>D> ABBOTT 300MG N20471 001 DEC 09, 1996 JUN CRLD
>A> + 300MG N20471 001 DEC 09, 1996 JUN CRLD
>D> + 600MG N20471 003 DEC 09, 1996 JUN DISC
>A> @ 600MG N20471 003 DEC 09, 1996 JUN DISC

>A> ZIPRASIDONE MESYLATE
>A> INJECTABLE; INTRAMUSCULAR
>A> GEODON
>A> + PFIZER EQ 20MG BASE/ML N20919 001 JUN 21, 2002 JUN NEWA

ZOLMITRIPTAN
TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT
>A> + ASTRAZENECA 5MG N21231 002 SEP 17, 2001 JUN NEWA

ACETAMINOPHEN
TABLET, EXTENDED RELEASE; ORAL
ACETAMINOPHEN

COREPHARMA	650MG	N76200 001	MAR 19, 2002	MAR	NEWA	

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
CONTAC 12 HOUR

@ GLAXOSMITHKLINE	8MG;75MG	N18099 001		JAN	DISC	

PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE

@ CENT PHARMS	8MG;75MG	N18809 001	MAY 07, 1984	FEB	DISC	

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE

TORPHARM	10MG	N75610 001	MAR 12, 2002	MAR	NEWA	

IBUPROFEN
TABLET; ORAL
IBUPROFEN

PERRIGO	200MG	N75995 001	MAR 14, 2002	MAR	NEWA	

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE; ORAL
ADVIL COLD AND SINUS

WYETH CONS	200MG;30MG	N21374 001	MAY 30, 2002	MAY	NEWA	

SUSPENSION; ORAL
CHILDREN'S ADVIL COLD

WYETH CONS	100MG/5ML;15MG/5ML	N21373 001	APR 18, 2002	APR	NEWA	

TABLET; ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HCL

PHARM FORM	200MG;30MG	N75588 001	APR 08, 2002	APR	NEWA	

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN

@ NOVO NORDISK	100 UNITS/ML	N18381 001		FEB	DISC	

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
>A> VELOSULIN BR

>A> + NOVO NORDISK	100 UNITS/ML	N21028 001	JUL 19, 1999	JUN	CMS2	

INSULIN SUSP ISOPHANE PURIFIED PORK
INJECTABLE; INJECTION
NPH PURIFIED PORK ISOPHANE INSULIN

@ NOVO NORDISK	100 UNITS/ML	N18623 001		FEB	DISC	

INSULIN ZINC SUSP PURIFIED PORK
INJECTABLE; INJECTION
LENTE

@ NOVO NORDISK	100 UNITS/ML	N18383 001		FEB	DISC

KETOPROFEN
TABLET; ORAL
KETOPROFEN

PERRIGO	12.5MG	N75364 001	FEB 07, 2002	FEB	NEWA

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)

CLAY PARK	5%	N75737 001	MAR 15, 2002	MAR	NEWA
NOVEX	5%	N75839 001	OCT 01, 2001	MAR	CTNA

PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
SUDAFED 12 HOUR

+	WARNER LAMBERT	120MG	N73585 001	OCT 31, 1991	MAY	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE '02

NO JUNE 2002 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
June 2002

Generic Name: albuterol
Trade Name: NONE ASSIGNED

Designated Indication: Prevention of paralysis due to spinal cord injury

Sponsor: MotoGen, Inc.
Address: 3 Pine View Road
Mount Kisco NY 10549

Date Designated: 3/12/2002
Market Approval Date: Not currently Approved

Generic Name: autologous antigen presenting cells pulsed with autologous tumor Ig idiotype
Trade Name: Mylovenge

Designated Indication: Treatment of multiple myeloma

Sponsor: Dendreon Corporation
Address: 3005 First Avenue
Seattle WA 98121

Date Designated: 4/18/2002
Market Approval Date: Not currently Approved

Generic Name: autologous tumor-derived gp96 heat shock protein-peptide complex
Trade Name: Oncophage

Designated Indication: Treatment of renal cell carcinoma

Sponsor: Antigenics, Inc.
Address: 34 Commerce Way
Woburn MA 01702

Date Designated: 5/10/2002
Market Approval Date: Not currently Approved

Generic Name: aztreonam
Trade Name: NONE ASSIGNED

Designated Indication: Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis

Sponsor: Corus Pharma
Address: 2025 First Ave., Suite 800
Seattle WA 98121

Date Designated: 3/12/2002
Market Approval Date: Not currently Approved

Generic Name: Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)
Trade Name: NONE ASSIGNED

Designated Indication: Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2

Sponsor: Excorp Medical, Inc.
Address: Suite 235
7200 Hudson Blvd.
Oakdale MN 55128

Date Designated: 2/11/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
June 2002

Generic Name: carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester
Trade Name: NONE ASSIGNED

Designated Indication: Management of cystic fibrosis

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc
Address: 900 Ridgebury Road
P.O. Box 368
Ridgefield CT 06877

Date Designated: 1/15/2002
Market Approval Date: Not currently Approved

Generic Name: clofarabine
Trade Name: Clofarex

Designated Indication: Treatment of acute myelogenous leukemia

Sponsor: Ilex Products, Inc.
Address: 4545 Horizon Hill Blvd.
San Antonio TX 78229-2263

Date Designated: 3/14/2002
Market Approval Date: Not currently Approved

Generic Name: clofarabine
Trade Name: Clofarex

Designated Indication: Treatment of acute lymphoblastic leukemia

Sponsor: Ilex Products, Inc.
Address: 4545 Horizon Hill Blvd.
San Antonio TX 78229-2263

Date Designated: 2/7/2002
Market Approval Date: Not currently Approved

Generic Name: creatine
Trade Name: Creapure

Designated Indication: Treatment of amyotrophic lateral sclerosis

Sponsor: Avicena Group, Inc.
Address: 580 California St.
Suite 1600
San Francisco CA 94104

Date Designated: 2/12/2002
Market Approval Date: Not currently Approved

Generic Name: genetically engineered herpes simplex virus (G207)
Trade Name: NONE ASSIGNED

Designated Indication: Tretament of malignant glioma

Sponsor: MediGene, Inc.
Address: 9880 Campus Point Drive, Suite A
San Diego CA 92121

Date Designated: 4/29/2002
Market Approval Date: Not currently Approved

Generic Name: homoharringtonine
Trade Name: NONE ASSIGNED

Designated Indication: Treatment for chronic myelogenous leukemia

Sponsor: American BioScience, Inc.
Address: 2730 Wilshire Blvd. #110
Santa Monica CA 90403

Date Designated: 2/8/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
June 2002

Generic Name:	human anti-transforming growth factor beta 1 monoclonal antibody	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of systemic sclerosis		
Sponsor:	Genzyme Corporation	Date Designated:	1/11/2002
Address:	One Kendall Square Cambridge MA 02139	Market Approval Date:	Not currently Approved

Generic Name:	hyaluronic acid	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency		
Sponsor:	Exhale Therapeutics, Inc.	Date Designated:	3/19/2002
Address:	1301 Shoreway Road Suite 320 Belmont CA 94002	Market Approval Date:	Not currently Approved

Generic Name:	I(131)-TM-601 (chlorotoxin)	Trade Name:	NONE ASSIGNED
Designated Indication:	treatment of malignant glioma		
Sponsor:	TransMolecular, Inc.	Date Designated:	2/14/2002
Address:	3800 Colonnade Parkway Suite 240 Birmingham AL 35243	Market Approval Date:	Not currently Approved

Generic Name:	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	Trade Name:	NONE ASSIGNED
Designated Indication:	Treatment of active chronic pouchitis		
Sponsor:	VSL Pharmaceuticals, Inc.	Date Designated:	1/15/2002
Address:	800 S. Frederick Avenue Gaithersburg MD 20877	Market Approval Date:	Not currently Approved

Generic Name:	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	Trade Name:	NONE ASSIGNED
Designated Indication:	Prevention of disease relapse in patients with chronic pouchitis		
Sponsor:	VSL Pharmaceuticals, Inc.	Date Designated:	1/15/2002
Address:	800 S. Frederick Ave. Gaithersburg MD 20877	Market Approval Date:	Not currently Approved

Generic Name:	lipase, amylase, and protease	Trade Name:	TheraCLEC-Total
Designated Indication:	Treatment of exocrine pancreatic insufficiency		
Sponsor:	Altus Biologics Inc.	Date Designated:	1/23/2002
Address:	625 Putnam Avenue Cambridge MA 02139	Market Approval Date:	Not currently Approved

Orphan Products Designations and Approvals List
June 2002

Generic Name: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea
Trade Name: NONE ASSIGNED

Designated Indication: Treatment of sickle cell disease

Sponsor: NeuroSearch A/S
Address: 93 Pederstrupvej
DK-2750 Ballerup
Denmark

Date Designated: 5/13/2002
Market Approval Date: Not currently Approved

Generic Name: nitazoxanide
Trade Name: Cryptaz

Designated Indication: Treatment of intestinal giardiasis

Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607

Date Designated: 2/14/2002
Market Approval Date: Not currently Approved

Generic Name: octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate
Trade Name: Aerugen

Designated Indication: Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis

Sponsor: Orphan Europe
Address: Immeuble "Le Wilson"
70 avenue du General de Gaulle, 92046 Paris
France

Date Designated: 5/16/2002
Market Approval Date: Not currently Approved

Generic Name: phenylephrine
Trade Name: NONE ASSIGNED

Designated Indication: Treatment of ileal pouch anal anastomosis related fecal incontinence

Sponsor: S.L.A. Pharma
Address: Unit 3, Hill Farm Industrial Estate
Leavesden, Watford
United Kingdom WD25 7SA

Date Designated: 2/14/2002
Market Approval Date: Not currently Approved

Generic Name: recombinant human endostatin protein
Trade Name: NONE ASSIGNED

Designated Indication: Treatment of metastatic melanoma

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive
Rockville MD 20850

Date Designated: 2/21/2002
Market Approval Date: Not currently Approved

Generic Name: recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3
Trade Name: SomatoKine

Designated Indication: Treatment of growth hormone insensitivity syndrome

Sponsor: Celtrix Pharmaceuticals, Inc. a subsidiary of
Address: 4851 Lake Brook Drive
Glen Allen VA 23060

Date Designated: 5/17/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
June 2002

Generic Name: retroviral gamma-c cDNA containing vector
Trade Name: NONE ASSIGNED
Designated Indication: Treatment of X linked severe combined immune deficiency disease
Sponsor: AVAX technologies, Inc.
Address: 9200 Indian Creek Parkway
Building 9, Suite 200
Overland Park KS 66210
Date Designated: 4/29/2002
Market Approval Date: Not currently Approved

Generic Name: rituximab
Trade Name: Rituxan
Designated Indication: Treatment of immune thrombocytopenic purpura
Sponsor: Genentech, Inc.
Address: 1 DNA Way
South San Francisco CA 94080-4990
Date Designated: 3/12/2002
Market Approval Date: Not currently Approved

Generic Name: S(-)-3-[3-amino-phthalimido]-glutaramide
Trade Name: NONE ASSIGNED
Designated Indication: Treatment of multiple myeloma
Sponsor: EntreMed Incorporated
Address: 9640 Medical Center Dr.
Rockville MD 20850
Date Designated: 3/14/2002
Market Approval Date: Not currently Approved

Generic Name: SS1(dsFv)-PE38
Trade Name: NONE ASSIGNED
Designated Indication: Treatment of malignant mesothelioma
Sponsor: NeoPharm Incorporated
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045
Date Designated: 2/11/2002
Market Approval Date: Not currently Approved

Generic Name: SS1(dsFv)-PE38
Trade Name: NONE ASSIGNED
Designated Indication: Treatment of epithelial ovarian cancer
Sponsor: NeoPharm, Inc.
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045
Date Designated: 2/11/2002
Market Approval Date: Not currently Approved

Generic Name: TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide
Trade Name: Oncomun
Designated Indication: Treatment of malignant glioma
Sponsor: Antisense Pharma GmbH
Address: Josef-Engert-Str. 9
93053 Regensberg
Germany
Date Designated: 6/5/2002
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
June 2002

Generic Name: tinidazole
Trade Name: NONE ASSIGNED

Designated Indication: Treatment of giardiasis

Sponsor: Presutti Laboratories, Inc.
Address: 1607 N. Douglas Ave.
Arlington Heights IL 60004

Date Designated: 4/18/2002
Market Approval Date: Not currently Approved

Generic Name: toralizumab
Trade Name: NONE ASSIGNED

Designated Indication: Treatment of immune thrombocytopenic purpura

Sponsor: IDEC Pharmaceuticals Corporation
Address: 3030 Callan Road
San Diego CA 92121

Date Designated: 3/14/2002
Market Approval Date: Not currently Approved

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 2002 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	6352684	NOV 28, 2009			
						NP	JUN 11, 2005
>ADD>	021212 001	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
>ADD>	021212 002	ALPROSTADIL;CAVERJECT					
	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27, 2018			
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27, 2018			
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	NOV 27, 2018			
	020883 001	ARGATROBAN;ARGATROBAN				I-352	APR 03, 2005
>ADD>	020702 001	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
>ADD>	020702 003	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
>ADD>	020702 004	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
	020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	6352684	NOV 28, 2009		NP	SEP 15, 2003
						NPP	MAY 10, 2005
	020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28, 2009		NP	SEP 15, 2003
						NPP	MAY 10, 2005
	021275 001	BIMATOPROST;LUMIGAN	6403649	SEP 21, 2012	U-446		
	020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	020613 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P				NPP	DEC 20, 2004
						PED	JUN 20, 2005
	018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
						PED	JAN 19, 2005
						W	JUL 19, 2004
						W	JAN 19, 2005
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
			5430057*PED	MAR 30, 2014	U-263	PED	AUG 04, 2002
			5559148*PED	NOV 24, 2015	U-264	PED	AUG 04, 2006
>ADD>	020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3		
>ADD>	020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3		
>ADD>	020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3		
>ADD>	021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5196444	JUN 04, 2012	U-3		
>ADD>	021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5196444	JUN 04, 2012	U-3		
	019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
			4525358*PED	DEC 25, 2007			
	019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
			4525358*PED	DEC 25, 2007			
	020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
			4525358*PED	DEC 25, 2007			
	020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U-223		
>ADD>	020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
>ADD>						PED	JAN 17, 2004
>ADD>	020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
>ADD>						PED	JAN 17, 2004
>ADD>	020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
>ADD>						PED	JAN 17, 2004
>ADD>	021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
>ADD>						PED	JAN 17, 2004
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX				I-349	FEB 27, 2005
	021165 001	DESLORATADINE;CLARINEX	6100274	JUL 07, 2019			
>ADD>	021312 001	DESLORATADINE;CLARINEX				NCE	DEC 21, 2006
	075863 001	DESOGESTREL;KARIVA				PC	JUN 04, 2002
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
>ADD>	021191 001	DIMYRISTOYL LECITHIN;IMAGENT				NCE	MAY 31, 2007
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
>ADD>	020972 001	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
>ADD>	020972 002	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
>ADD>	020972 003	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
>ADD>	020796 001	ENTACAPONE;COMTAN	5446194	AUG 29, 2012			
>ADD>			5135950	OCT 31, 2010			
>ADD>			4963590	NOV 27, 2007			
>ADD>			5112861	MAY 12, 2009			
>ADD>	020718 001	EPTIFIBATIDE;INTEGRILIN	5968902	JUN 02, 2015	U-453		
>ADD>			5747447	MAY 05, 2015			
>ADD>	020718 002	EPTIFIBATIDE;INTEGRILIN	5968902	JUN 02, 2015	U-453		
>ADD>			5747447	MAY 05, 2015			
	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	6369085	MAY 25, 2018			
	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	6369085	MAY 25, 2018			
	020655 001	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 002	ESTRADIOL;ALORA				I-351	APR 05, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020655 003	ESTRADIOL;ALORA				I-351	APR 05, 2005
	020655 004	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
			5227169	MAY 17, 2011			
			5212199	MAY 17, 2011			
			5164190	DEC 11, 2010			
	020538 005	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 006	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 007	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	020538 008	ESTRADIOL;VIVELLE-DOT				I-254	AUG 16, 2003
	075753 002	FENOFIBRATE;FENOFIBRATE (MICRONI				PC	SEP 15, 2002
	075753 003	FENOFIBRATE;FENOFIBRATE (MICRONI				PC	SEP 15, 2002
	075442 001	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	075442 002	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
	075442 003	FLECAINIDE ACETATE;FLECAINIDE ACETATE				PC	OCT 28, 2002
>ADD>	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				D-75	JUN 12, 2005
>ADD>	018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM				D-75	JUN 12, 2005
>ADD>	020121 001	FLUTICASONE PROPIONATE;FLONASE				D-76	MAY 23, 2005
	021345 001	FONDAPARINUX SODIUM;ARIXTRA	4818816	AUG 19, 2003			
>ADD>	021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
	020235 001	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020235 002	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020235 003	GABAPENTIN;NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
			5084479*PED	JUL 02, 2010	U-258		
	020882 001	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
	020882 002	GABAPENTIN;NEURONTIN				I-354	MAY 24, 2005
>ADD>	021129 001	GABAPENTIN;NEURONTIN	6054482	APR 25, 2017		I-354	MAY 24, 2005
>ADD>			6054482*PED	OCT 25, 2017			
	020622 001	GLATIRAMER ACETATE;COPAXONE	6342476	MAY 24, 2014	U-441		
			6362161	MAY 24, 2014	U-441		
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 20, 2007	U-105		
	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
			4743450	FEB 24, 2007		PED	JUN 28, 2003
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
			4344949	OCT 03, 2002	U-3		
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3		
			4743450	FEB 24, 2007			
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
>ADD>	020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
>ADD>	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
	020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
	020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009			
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	6348216	JUN 10, 2017			
>ADD>	021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
>ADD>			5071643*PED	JUN 10, 2009			
>ADD>			5360615	DEC 10, 2008			
>ADD>			5360615*PED	JUN 10, 2009			
	021373 001	IBUPROFEN;CHILDREN'S ADVIL COL				NP	AUG 01, 2003
						PED	FEB 01, 2004
	075874 001	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
	075874 002	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
	020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011			
	020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011			
	020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011			
>ADD>	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	6403569	APR 28, 2020	U-449		
>ADD>	020657 001	ITRACONAZOLE;SPORANOX	6407079	JUN 18, 2019			
>ADD>	020966 001	ITRACONAZOLE;SPORANOX	6407079	JUN 18, 2019			
	019700 001	KETOROLAC TROMETHAMINE;ACULAR				M-16	FEB 08, 2005
	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE				M-16	FEB 08, 2005
>ADD>	020564 001	LAMIVUDINE;EPIVIR				D-2	JUN 24, 2005
>ADD>	020564 003	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NS	JUN 24, 2005
>ADD>			5047407*PED	MAY 17, 2010		D-2	JUN 24, 2005
>ADD>			5905082	MAY 18, 2016			
>ADD>			5905082*PED	NOV 18, 2016			
>ADD>			6180639	JAN 30, 2018	U-248		
>ADD>			6180639*PED	JUL 30, 2018	U-248		
>ADD>	020596 001	LAMIVUDINE;EPIVIR				D-2	JUN 24, 2005
>ADD>	020406 001	LANSOPRAZOLE;PREVACID	5013743	FEB 12, 2010	U-452		
>ADD>	020406 002	LANSOPRAZOLE;PREVACID	5013743	FEB 12, 2010	U-452		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021343 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014			
			5733950	OCT 03, 2008			
			5739176	OCT 03, 2008			
			4938763	OCT 03, 2008			
			5278201	JAN 11, 2011			
			5324519	OCT 20, 2011			
	021088 001	LEUPROLIDE ACETATE;VIADUR	6375978	DEC 17, 2018			
			6395292	JAN 30, 2017			
	020634 001	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
	020634 002	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
	020634 003	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
						I-357	APR 08, 2003
	020635 001	LEVOFLOXACIN;LEVAQUIN				I-357	APR 08, 2003
	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-357	APR 08, 2003
	020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
			5138069	AUG 11, 2009			
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
	020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
			5138069*PED	FEB 11, 2010			
			5153197*PED	APR 06, 2010	U-3		
			5608075*PED	SEP 04, 2014			
>ADD>	021249 001	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
>ADD>			6129930	SEP 20, 2013	U-448		
>ADD>			6406715	JUN 18, 2022	U-450		
>ADD>	021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
>ADD>			6129930	SEP 20, 2013	U-448		
>ADD>			6406715	JUN 18, 2022	U-450		
>ADD>	021249 003	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
>ADD>			6129930	SEP 20, 2013	U-448		
>ADD>			6406715	JUN 18, 2022	U-450		
	019643 002	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
						I-350	FEB 14, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019643 003	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
						I-350	FEB 14, 2005
	019643 004	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
						I-350	FEB 14, 2005
	076175 001	MEFLOQUINE HYDROCHLORIDE;MEFLOQUINE HCL				PC	NOV 03, 2002
	020922 001	MEQUINOL;SOLAGE	6353029	AUG 24, 2020			
>ADD>	013217 001	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
						I-320	DEC 15, 2003
						W	DEC 15, 2003
						W	JUN 15, 2004
	021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4519801	JUL 12, 2002		NP	AUG 01, 2003
			4612008	SEP 16, 2003			
			4783337	SEP 16, 2003	U-372		
			5082668	SEP 16, 2003			
>ADD>	021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020			
>ADD>	021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA				NP	JUN 07, 2005
>ADD>	021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA				NP	JUN 07, 2005
>ADD>	021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA				NP	JUN 07, 2005
	020415 001	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	020415 002	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	020415 003	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
	021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
	021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
>ADD>	020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
>ADD>			5256664	APR 28, 2012			
>ADD>			4338317*PED	SEP 16, 2003			
>ADD>			5256664*PED	OCT 28, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
>ADD>			5256664	APR 28, 2012			
>ADD>			4338317*PED	SEP 16, 2003			
>ADD>			5256664*PED	OCT 28, 2012			
>ADD>	020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
>ADD>			5256664	APR 28, 2012			
>ADD>			4338317*PED	SEP 16, 2003			
>ADD>			5256664*PED	OCT 28, 2012			
>ADD>	020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
>ADD>			5256664	APR 28, 2012			
>ADD>			4338317*PED	SEP 16, 2003			
>ADD>			5256664*PED	OCT 28, 2012			
>ADD>	020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
>ADD>			5256664	APR 28, 2012			
>ADD>			4338317*PED	SEP 16, 2003			
>ADD>			5256664*PED	OCT 28, 2012			
>ADD>	020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317	MAR 16, 2003			
>ADD>			5256664	APR 28, 2012			
>ADD>			4338317*PED	SEP 16, 2003			
>ADD>			5256664*PED	OCT 28, 2012			
>ADD>	020778 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
>ADD>	020779 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
>ADD>	020381 001	NIACIN;NIASPAN	6406715	JUN 18, 2022	U-450		
>ADD>	020381 002	NIACIN;NIASPAN	6406715	JUN 18, 2022	U-450		
>ADD>	020381 003	NIACIN;NIASPAN	6406715	JUN 18, 2022	U-450		
>ADD>	020381 004	NIACIN;NIASPAN	6406715	JUN 18, 2022	U-450		
>ADD>	020381 005	NIACIN;NIASPAN TITRATION ST	6406715	JUN 18, 2022	U-450		
>ADD>			6129930	SEP 20, 2013	U-354		
	020076 004	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020076 005	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020076 006	NICOTINE;HABITROL				D-71	NOV 12, 2002
	020555 001	NIZATIDINE;AXID AR	4375547	APR 12, 2002			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	6395292	JAN 30, 2017			
	021286 001	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	021286 003	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	021286 004	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
	019810 001	OMEPRAZOLE;PRILOSEC	4636499*PED	NOV 30, 2005			
			6166213*PED	APR 19, 2019			
	019810 002	OMEPRAZOLE;PRILOSEC	4636499*PED	NOV 30, 2005			
			6166213*PED	APR 19, 2019			
	019810 003	OMEPRAZOLE;PRILOSEC	4636499*PED	NOV 30, 2005			
			6166213*PED	APR 19, 2019			
	020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009			
	021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
			4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
			5266331	OCT 26, 2007			
			5549912	OCT 26, 2007			
			5508042	APR 16, 2013	U-443		
			5656295	OCT 26, 2007	U-443		
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-356	APR 19, 2005
	020987 002	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		I-356	APR 19, 2005
>ADD>						I-330	JUN 12, 2004
>ADD>						NCE	FEB 02, 2005
>ADD>	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
>ADD>			5872132	MAY 19, 2015		I-326	APR 13, 2004
>ADD>			5900423	MAY 19, 2015		I-345	DEC 14, 2004
>ADD>			5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
>ADD>			6063927	APR 23, 2019		PED	JUN 14, 2005
>ADD>			6080759	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6113944*PED	JUN 14, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
>ADD>			5872132	MAY 19, 2015		I-326	APR 13, 2004
>ADD>			5900423	MAY 19, 2015		I-345	DEC 14, 2004
>ADD>			5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
>ADD>			6063927	APR 23, 2019		PED	JUN 14, 2005
>ADD>			6080759	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6113944*PED	JUN 14, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
>ADD>			5872132	MAY 19, 2015		I-326	APR 13, 2004
>ADD>			5900423	MAY 19, 2015		I-345	DEC 14, 2004
>ADD>			5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
>ADD>			6063927	APR 23, 2019		PED	JUN 14, 2005
>ADD>			6080759	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6113944*PED	JUN 14, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
>ADD>			5872132	MAY 19, 2015		I-326	APR 13, 2004
>ADD>			5900423	MAY 19, 2015		I-345	DEC 14, 2004
>ADD>			5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
>ADD>			6063927	APR 23, 2019		PED	JUN 14, 2005
>ADD>			6080759	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			6113944	DEC 14, 2014			
>ADD>			6133289	MAY 15, 2015	U-358		
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			6172233	JAN 15, 2018			
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6113944*PED	JUN 14, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
>ADD>			5872132	MAY 19, 2015		I-326	APR 13, 2004
>ADD>			5900423	MAY 19, 2015		I-345	DEC 14, 2004
>ADD>			5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
>ADD>			6063927	APR 23, 2019		PED	JUN 14, 2005
>ADD>			6080759	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			6113944	DEC 14, 2014			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 15, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6113944*PED	JUN 14, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
>ADD>			5811436	SEP 22, 2015		PED	NOV 17, 2002
>ADD>			5872132	MAY 19, 2015			
>ADD>			5900423	MAY 19, 2015			
>ADD>			5789449	JAN 06, 2009	U-285		
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007			
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5811436*PED	MAR 22, 2016			
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
>ADD>			5900423	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			5789449	JAN 06, 2009	U-285		
>ADD>			4721723	DEC 29, 2006	U-12		
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
>ADD>			5900423	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			5789449	JAN 06, 2009	U-285		
>ADD>			4721723	DEC 29, 2006	U-12		
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
>ADD>			5900423	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			5789449	JAN 06, 2009	U-285		
>ADD>			4721723	DEC 29, 2006	U-12		
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
>ADD>			5900423	MAY 19, 2015		PED	NOV 17, 2002
>ADD>			5789449	JAN 06, 2009	U-285		
>ADD>			4721723	DEC 29, 2006	U-12		
>ADD>			6062927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-358		
>ADD>			6172233	JAN 15, 2018			
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>			4721723*PED	JUN 29, 2007	U-12		
>ADD>			5789449*PED	JUL 06, 2009	U-285		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6121291*PED	SEP 17, 2017	U-431		
>ADD>			6133289*PED	NOV 19, 2015	U-358		
>ADD>			6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
>ADD>			4839177	JUN 13, 2006		PED	AUG 12, 2005
>ADD>			5422123	JUN 06, 2012			
>ADD>			4721723	DEC 29, 2006			
>ADD>			5900423	MAY 19, 2015			
>ADD>			5789449	JAN 06, 2009	U-286		
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-286		
>ADD>			6172233	JAN 15, 2018			
>ADD>			4721723*PED	JUN 29, 2007			
>ADD>			4839177*PED	DEC 13, 2006			
>ADD>			5422123*PED	DEC 06, 2012			
>ADD>			5789449*PED	JUL 06, 2009	U-286		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6133289*PED	NOV 19, 2015	U-286		
>ADD>			6172233*PED	JUL 15, 2018			
>ADD>	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
>ADD>			4839177	JUN 13, 2006		PED	AUG 12, 2005
>ADD>			5422123	JUN 06, 2012			
>ADD>			4721723	DEC 29, 2006			
>ADD>			5900423	MAY 19, 2015			
>ADD>			5789449	JAN 06, 2009	U-286		
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-286		
>ADD>			6172233	JAN 15, 2018			
>ADD>			4721723*PED	JUN 29, 2007			
>ADD>			4839177*PED	DEC 13, 2006			
>ADD>			5422123*PED	DEC 06, 2012			
>ADD>			5789449*PED	JUL 06, 2009	U-286		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6133289*PED	NOV 19, 2015	U-286		
>ADD>			6172233*PED	JUL 15, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		I-358	FEB 12, 2005
>ADD>			4839177	JUN 13, 2006		PED	AUG 12, 2005
>ADD>			5422123	JUN 06, 2012			
>ADD>			5789449	JAN 06, 2009	U-286		
>ADD>			5872132	MAY 19, 2015			
>ADD>			5900423	MAY 19, 2015			
>ADD>			6063927	APR 23, 2019			
>ADD>			6080759	MAY 19, 2015			
>ADD>			6121291	MAR 17, 2017	U-286		
>ADD>			6133289	MAY 19, 2015	U-286		
>ADD>			6172233	JAN 15, 2018			
>ADD>			4721723*PED	JUN 29, 2007			
>ADD>			4839177*PED	DEC 13, 2006			
>ADD>			5422123*PED	DEC 06, 2012			
>ADD>			5789449*PED	JUL 06, 2009	U-286		
>ADD>			5872132*PED	NOV 19, 2015			
>ADD>			5900423*PED	NOV 19, 2015			
>ADD>			6063927*PED	OCT 23, 2019			
>ADD>			6080759*PED	NOV 19, 2015			
>ADD>			6121291*PED	SEP 17, 2017	U-286		
>ADD>			6133289*PED	NOV 19, 2015	U-286		
>ADD>			6172233*PED	JUL 15, 2018			
	020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	SEP 24, 2010			
	021302 001	PIMECROLIMUS;ELIDEL	6352998	OCT 26, 2015			
			6352998*PED	APR 26, 2016			
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
>ADD>	019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
>ADD>			5180589	JUL 09, 2008		I-304	JAN 18, 2003
>ADD>			5030447	JUL 09, 2008		I-287	FEB 10, 2003
>ADD>			5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
>ADD>			4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
>ADD>			5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
>ADD>			5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
>ADD>			5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
>ADD>						PED	JUL 18, 2003
>ADD>						PED	AUG 10, 2003
>ADD>						PED	JUN 18, 2005
>ADD>						PED	JUL 18, 2003
>ADD>						PED	JUN 18, 2005
>ADD>	019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
>ADD>			5030447	JUL 09, 2008		I-304	JAN 18, 2003
>ADD>			5180589	JUL 09, 2008		I-287	FEB 10, 2003
>ADD>			5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
>ADD>			4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
>ADD>			5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
>ADD>			5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
>ADD>			5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
>ADD>						PED	JUL 18, 2003
>ADD>						PED	AUG 10, 2003
>ADD>						PED	JUN 18, 2005
>ADD>						PED	JUL 18, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						PED	JUN 18, 2005
>ADD>							
>ADD>	019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
>ADD>			5030447	JUL 09, 2008		I-304	JAN 18, 2003
>ADD>			5180589	JUL 09, 2008		I-287	FEB 10, 2003
>ADD>			5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
>ADD>			4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
>ADD>			5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
>ADD>			5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
>ADD>			5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
>ADD>						PED	JUL 18, 2003
>ADD>						PED	AUG 10, 2003
>ADD>						PED	JUN 18, 2005
>ADD>						PED	JUL 18, 2003
>ADD>						PED	JUN 18, 2005
>ADD>							
>ADD>	019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
>ADD>			5030447	JUL 09, 2008		D-70	DEC 18, 2004
>ADD>			5180589	JUL 09, 2008		PED	JUN 18, 2005
>ADD>			5622985	APR 22, 2014	U-335	PED	JUN 18, 2005
>ADD>			4346227*PED	APR 20, 2006			
>ADD>			5180589*PED	JAN 09, 2009			
>ADD>			5622985*PED	OCT 22, 2014	U-335		
>ADD>			5030447*PED	JAN 09, 2009			
>ADD>	019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
			4743450	FEB 24, 2007			
			5684016	NOV 04, 2014	U-210		
			5747504	APR 10, 2005	U-210		
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
			5684016*PED	MAY 04, 2015	U-210		
			5747504*PED	OCT 10, 2005	U-210		
	019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
			4743450	FEB 24, 2007			
			5684016	NOV 04, 2014	U-210		
			5747504	APR 10, 2005	U-210		
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
			5684016*PED	MAY 04, 2015	U-210		
			5747504*PED	OCT 10, 2005	U-210		
	019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
			4743450	FEB 24, 2007			
			5684016	NOV 04, 2014	U-210		
			5747504	APR 10, 2005	U-210		
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
			5684016*PED	MAY 04, 2015	U-210		
			5747504*PED	OCT 10, 2005	U-210		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
			4743450	FEB 24, 2007			
			5684016	NOV 04, 2014	U-210		
			5747504	APR 10, 2005	U-210		
			4344949*PED	APR 03, 2003	U-3		
			4743450*PED	AUG 24, 2007			
			5684016*PED	MAY 04, 2015	U-210		
			5747504*PED	OCT 10, 2005	U-210		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2003			
>ADD>	020903 001	RIBAVIRIN;REBETOL	6177074	NOV 01, 2016	U-454		
>ADD>			6177074*PED	MAY 01, 2017	U-454		
	020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013			
	020835 001	RISEDRONATE SODIUM;ACTONEL				D-73	MAY 17, 2005
						D-74	MAY 17, 2005
	020835 002	RISEDRONATE SODIUM;ACTONEL				D-73	MAY 17, 2005
						D-74	MAY 17, 2005
	020272 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 004	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 005	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 007	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020272 008	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020588 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
	021042 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021042 003	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017			
	021052 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	021052 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
			6063811	MAY 06, 2017	U-266		
	020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
	020692 001	SALMETEROL XINAFOATE;SEREVENT				I-348	MAR 22, 2005
	020828 001	SAQUINAVIR;FORTOVASE	6352717	NOV 16, 2019			
			6008228	JUN 06, 2015			
	021209 001	SECRETIN;SECREFLO				NP	APR 04, 2005
						ODE	APR 04, 2009
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	5248699*PED	FEB 13, 2013	U-12	I-355	MAY 16, 2005
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-355	MAY 16, 2005
	020478 001	SEVOFLURANE;ULTANE				M-17	MAR 30, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007			
			5436272	JUL 25, 2012	U-439		
	020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
	020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U-136		
	021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5912015	MAR 12, 2012			
	020604 004	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
	020677 001	SPARFLOXACIN;ZAGAM	4795751	FEB 04, 2010	U-160		
	020132 001	SUMATRIPTAN SUCCINATE;IMITREX	6368627	MAR 02, 2012	U-444		
	020132 002	SUMATRIPTAN SUCCINATE;IMITREX	6368627	MAR 02, 2012	U-444		
	020132 003	SUMATRIPTAN SUCCINATE;IMITREX	6368627	MAR 02, 2012	U-444		
	017970 001	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
			4536516*PED	FEB 20, 2003			
	017970 002	TAMOXIFEN CITRATE;NOLVADEX	4536516	AUG 20, 2002			
			4536516*PED	FEB 20, 2003			
	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004			
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004			
	020846 001	TERBINAFINE;LAMISIL	4755534	DEC 30, 2006	U-445		
			4680291	JUL 14, 2004	U-445		
	020791 001	TESTOSTERONE;TESTODERM TTS	6348210	NOV 10, 2019	U-440		
	020785 001	THALIDOMIDE;THALOMID	6315720	OCT 23, 2020	U-442		
	020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
	020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
	021228 001	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
	021228 002	TOLTERODINE TARTRATE;DETROL LA	5559269	NOV 05, 2013	U-318		
>ADD>	021272 001	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021272 002	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
>ADD>	021272 003	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
>ADD>	021272 004	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U-455	NCE	MAY 21, 2007
						ODE	MAY 21, 2009
	021289 001	UROFOLLITROPIN;BRAVELLE				NP	MAY 06, 2005
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
			5879706	JAN 19, 2016			
			6107302	JAN 19, 2016			
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009			
			5879706	JAN 19, 2016			
			6107302	JAN 19, 2016			
	020593 001	VALPROATE SODIUM;DEPACON				D-72	JAN 24, 2005
	021283 001	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		
	021283 002	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		
	021283 003	VALSARTAN;DIOVAN	6294197	JUN 18, 2017	U-3		
>ADD>	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6403120	MAR 20, 2017	U-451		
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6403120	MAR 20, 2017	U-451		
>ADD>	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6403120	MAR 20, 2017	U-451		
>ADD>	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6403120	MAR 20, 2017	U-451		
>ADD>	021119 001	VERTEPORFIN;VISUDYNE	4883790	JAN 20, 2007			
	021266 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021266 002	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021267 001	VORICONAZOLE;VFEND				NCE	MAY 24, 2007
	021036 001	ZANAMIVIR;RELENZA	6294572	DEC 15, 2014			
>ADD>	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
>ADD>	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
>ADD>	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
>ADD>	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019			
>ADD>	020919 001	ZIPRASIDONE MESYLATE;GEODON	6399777	APR 01, 2017		NCE	FEB 05, 2006
>ADD>			4831031	MAR 02, 2007			
>ADD>			6110918	MAR 26, 2017			
>ADD>			6232304	APR 01, 2017			
>ADD>	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012			
	020789 001	ZONISAMIDE;ZONEGRAN	6342515	DEC 21, 2018	U-438		

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES

NEW DOSING SCHEDULE

D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER

MISCELLANEOUS EXCLUSIVITY CODES

M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

PATENT USE CODES

U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	METHOD OF TREATING
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15

*U.S. Government Printing Office: 2002 — 491-214/40014

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.

For privacy protection, check the box below:

Γ Do not make my name available to other mailers.

Please choose method of payment:

Γ Check payable to Superintendent of Documents
Γ GPO Deposit Account ΓΓΓΓΓΓ-Γ
Γ VISA or MasterCard
ΓΓΓΓΓΓΓΓΓΓΓΓΓΓΓΓ

_____
(Credit card expiration date)

_____
(Authorizing Signature)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

Thank you for your order!

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence

C:355661 M:174736 O:12937927